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Abstract
Base-mediated formation of N-hydroxy- and N-alkoxyindoles, synthesis of dilemmaones A
and B, and novel efforts in indole methodology and total synthesis

Katharine E. Lambson
A novel and facile base-mediated formation of N-hydroxy- and N-alkoxyindoles from
2-(2-nitrophenyl)butenoates has been developed. Either potassium tert-butoxide in tertbutanol or sodium tert-pentoxide in toluene, with or without the subsequent addition of an
electrophile, can be used to afford an array of N-oxyindoles. The first total syntheses of
dilemmaones A and B has been accomplished, utilizing Kosugi-Migita-Stille couplings and a
reductive cyclization of an epoxide precursor with hydrogen gas in the presence of either
palladium on carbon or platinum oxide as the key steps. Progress toward the total
synthesis of dilemmaone C using similar methodology has been made. Additional
methodological work, including screening of a regioselective Mizoroki-Heck reaction to
form o-nitrostyrenes has been performed. Work toward the synthesis of the
marinoquinolines has been studied, wherein the key step in precursor synthesis is a onepot condensation and cyclization to form the quinoline core.
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Chapter 1—Base-catalyzed cyclization to form N-alkoxy and N-hydroxyindoles
I.

Introduction
N-hydroxy- and N-alkoxyindoles have received an increased amount of attention over

the last decades for several reasons. Both classes of compounds are present in an array of
biologically active natural and synthetic products.1 Examples of structurally diverse natural
compounds that contain either an N-hydroxy- or N-alkoxyindole core include the cytotoxic
compound stephacidin B (1),2 tetrahydro-β-carboline derivative 2,3 and (R)-paniculidine B
(3)4 (Figure 1). Additionally, synthetic N-hydroxyindoles such as 4 can act as powerful
inhibitors of human lactate dehydrogenase isoform A (LDH-A).5 Further, derivatives of
indole-3-carbinol such as N-alkoxyindole 5 (Figure 1), have been shown to enhance the I3Cinduced G1 cell cycle arrest of human breast cancer cells.6 N-hydroxy-and N-alkoxyindoles
have additionally found widespread use as synthetic intermediates, particularly toward the
production of previously difficult-to-access precursors to indole alkaloids.7

Figure 1. Structures of bioactive natural products 1-3 and synthetic compounds 4 and 5.
1

There are a number of reported synthetic routes to N-hydroxyindoles. Some
examples of how these compounds can be formed are by the oxidations of indoles8 and
indolines,9 reductive cyclizations of 2-(2-nitrophenyl)-aldehydes and -ketones,10 BatchoLeimgruber type indole synthesis,11 annulation of nitrosoarenes with alkynes12 and
rhodium-catalyzed cyclization of arylnitrones13 (Scheme 1). N-alkoxyindoles have only been
obtained by alkylation of the corresponding N-hydroxyindole derivatives in the presence of
a base.14, 15

Scheme 1. Previously reported transformations to N-hydroxyindoles.
Of particular note to this research is the report by Wróbel and Mąkosza of three
examples of the conversion of tert-butyl 2-(2-nitroaryl)butanoates to N-hydroxyindole
derivatives in the presence of a strong base.16 One example illustrated in Scheme 2
showcases the treatment of tert-butyl 2-(5-chloro-2-nitrophenyl)butanoate with sodium

2

hydroxide in a mixed solvent system to afford tert-butyl 5-chloro-N-hydroxyindole-3carboxylate in moderate yield.

Scheme 2. Cyclization of a tert-butyl 2-(5-chloro-2-nitrophenyl)butanoate.
Previously reported in our lab by Dr. Sergei Banini is an example of a related
cyclization using ethyl 2-(5-methoxy-2-nitrophenyl)butenoate (6).17 The substrate was
deprotonated with potassium tert-butoxide followed by addition of methyl iodide with the
intent to trap reactive intermediates (Scheme 3). Interestingly, he isolated only Nmethoxyindole 8 without a trace of other alkylation products. It is noteworthy to mention
that treatment of the corresponding nitrile, 7, under the same reaction conditions only
yielded quinoline N-oxide 9 (Scheme 3).

Scheme 3. Cyclization of 6 to N-methoxyindole 8 or of 7 to quinoline N-oxide 9.
In addition to the example of the formation of N-methoxyindole 8 seen in Scheme 3, Dr. Nurul
Ansari of the Söderberg lab recently described a related cyclization of 2-nitroimine
derivatives to yield N-methoxybenzimidazoles (Scheme 4).18 Based on the observation that
2-(2-nitroaryl)butenoates esters can be transformed into N-alkoxyindoles, we sought to
expand on this transformation. Herein is described the scope and limitations of the direct
and facile base-mediated synthesis of N-hydroxy- and N-alkoxyindoles.

3

Scheme 4. Formation of N-methoxybenzimidazoles from 2-nitro-N-(2-methyl-1-propen-1yl)benzenamines.
II.

Results and Discussion
The discovery of a base-mediated formation of N-methoxyindoles was initially

observed by Dr. Banini during his attempts to probe the effects of nitrile versus ester
functionalized cyclization precursors. The conditions shown in Scheme 3 were originally
selected in his efforts to understand the preference of nitrile-substituted precursors for
cyclization to quinolines, while ester-substituted precursors favored cyclization to Nalkoxyindoles. With the formation of N-methoxyindole 8 observed under basic, non-catalytic
conditions, we sought to probe the versatility of this type of transformation. Using precursor
6 as a model substrate, two additional 2-(2-nitroaryl)butenoates were prepared. Ethyl ester
10 was synthesized as shown in Scheme 5 according to literature reports, and the
corresponding methyl ester 11 was prepared according to a previously reported
methodology.19

Scheme 5. Synthesis of compound 10.
Dr. Banini pioneered the work outlined in Table 1. He found that, utilizing the same
conditions as described in Scheme 3 for the cyclization of ester-derivatives, precursors 10
4

and 11 also reacted to form N-alkoxyindoles. Precursor 10 underwent one-pot cyclization
and alkylation with methyl iodide to form N-methoxyindole 12 in good yield (Table 1, entry
1). Methyl ester precursor 11 reacted to form methyl N-methoxy-3-indolecarboxylate (15)
in 74% yield (Table 1, entry 4). Notably, compound 15 is a naturally-occurring antifungal
metabolite produced by Wasabi (Wasabia japonica) in response to plant infection.20 This
alkaloid has also been isolated from the wild crucifer Arabidopsis thaliana.21 The preparation
of 11 and subsequent transformation to 15 illustrates a novel and efficient method for the
preparation of this natural product.22 For both precursors 10 and 11, electrophiles other
than methyl iodide could be used. N-benzyloxyindole 13 and N-allyloxyindole 14 (Table 1,
entries 2-3) were obtained in good yields from reactions with benzyl bromide and allyl
bromide, respectively.
Table 1. Formation of N-alkoxyindoles using potassium tert-butoxide.

Entry 2-(2-nitrophenyl)butanoate

R’-X

N-alkoxyindolea,b

1
2
3
4

Me-I
Bn-Br
Allyl-Br
Me-I

12 (R = Et, R’ = Me, 84%)
13 (R = Et, R’ = Bn, 78%)
14 (R = Me, R’ = CH2CH=CH2, 91%)
15 (R = Me, R’ = Me, 74%)

10 (R = Et)
10 (R = Et)
11 (R = Me)
11 (R = Me)

a General

conditions for the preparation of N-alkoxyindoles: 11 equiv. of t-BuOK,
then 1.5 equiv. of alkylhalide. See experimental section for full details.
b Yield of pure product isolated after chromatography.
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Despite the promising data reported in Table 1, the results lacked reproducibility and the
values given in the Table are the best yields observed from several attempts by Dr. Banini
and myself.
In an effort to develop a more consistent means of producing N-alkoxyindoles, we
explored an alternate hindered base. Sodium tert-pentoxide was selected due to its
commercial availability in solution and solubility in a variety of organic solvents. Treatment
of 11 with sodium tert-pentoxide in toluene, in place of potassium tert-butoxide in tertbutanol, followed by addition of methyl iodide under the reaction conditions described in
Table 2 (entry 1) did not yield the expected N-methoxyindole 12. Rather, the corresponding
N-hydroxyindole 19 was obtained as the only observed product. In an effort to encourage
the formation of 12, the amount of base was sequentially decreased. It was found that under
all conditions using greater than 2 equivalents of base, the only isolated product was Nhydroxyindole 19 (Table 2, entries 2-3). Indeed, even when the amount of base was
decreased further, 19 remained the major product, and N-methoxyindole 12 was isolated in
only 5% yield as an inseparable mixture with 32% unreacted starting material 10 (Table 2,
entry 4). To confirm that this type of cyclization does not require the presence of an alkyl
halide such as MeI to proceed, 10 was reacted with 2.3 equivalents of base without the
addition of methyl iodide (Table 2, entry 5). As expected, N-hydroxyindole 19 was isolated
as the sole product, albeit in slightly lower isolated yield. The reason for this observation is
unknown.
Further examination of similar alkyl halides (Table 2, entries 6-7) illustrated
consistent results, in that 19 was isolated as the sole product, while the corresponding Nalkoxyindoles (13 or 16) were not observed. This formation of N-hydroxyindoles is most
6

similar to the work done by Wróbel and Mąkosza, and yields are comparable across the two
studies.16 It is worth noting that, using the reaction conditions reported in Table 2, quinoline
N-oxides were never observed. Despite alkyl halides being unsuitable reagents for the
preparation of N-alkoxyindoles under these reaction conditions, three alternate
electrophiles, acetic anhydride, tosyl chloride, and dimethylsulfate (DMS), were screened
(Table 2, entries 8-10). In these three cases, the reactions all proceeded smoothly to produce
N-oxygenated indoles 17, 18, and 12.
Table 2 Optimization of the formation of N-hydroxy- and N-alkoxyindoles from 10.a,b

Entry
1
2
3
4
5
6
7
8
9
10

Equiv. base
11
5
2.3
1.1
2.3
2.3
2.3
2.3
2.3
2.3

R-X (3 equiv.)
MeI
MeI
MeI
MeI
1-bromohexane
BnBr
Ac2O
TsCl
DMSd

N-Alkoxyindole

12 (5%)c
16 (-)
13 (-)
17 (48%)
18 (44%)
12 (54%)

N-Hydroxyindole
19 (52%)
19 (51%)
19 (52%)
19 (23%)
19 (42%)
19 (47%)
19 (18%)

a See

experimental section for details. The methodology for entries 1-4 differs only in the
equiv. of base used.
b Yields are of pure product isolated after chromatography, unless otherwise noted.
c Inseparable mixture of starting material (32%) and 12 (5%) as determined by 1H-NMR.
d DMS = dimethyl sulfate.
With a consistent means of forming both N-hydroxy- and N-alkoxyindoles thus
developed, we turned our attention to the tolerance of the reaction conditions to an
expanded array of substrates. First, we chose to examine the effect of a longer alkyl chain to
7

determine if groups larger than formaldehyde would be eliminated over the course of the
cyclization (see Scheme 10 for a mechanistic explanation). Our initial approach to forming
longer chain 2-(2-nitroaryl)alkenoates involved a concurrent Wittig/iodination reaction
followed by a Kosugi-Migita-Stille coupling (Scheme 6).

Scheme 6. Proposed route to 2-(2-nitroaryl)alkenoates.
With this in mind, we endeavored to synthesize a variety of ethyl 2-iodo-2-alkenoates using
a one-pot reaction involving a Wittig reaction23 and olefin iodination.24 The compounds
made using this methodology are outlined in Table 3.
Of the aldehydes screened using this methodology, it was found that the unbranched
varieties readily condensed to their corresponding alkenoates in good to excellent yields
(Table 3, entries 1-4). Although branched aldehydes such as cyclohexanecarboxaldehyde
and 2-phenylpropionaldehyde (Table 3, entries 5 and 6, respectively) condensed to afford
the desired products, the yields dropped considerably, presumably due to greater steric
hindrance around the site of condensation. All compounds made using this method (20-25)
were obtained as inseparable mixtures of E/Z stereoisomers. Additionally, these compounds
display significant instability in deuterated solvents. It was observed that, upon dissolution
in chloroform-d for NMR analysis, the solutions (all starting as pale yellow to orange in color)
turned pink over the course of time ranging from seconds to 30 minutes. Based upon 1H NMR
analysis, it is surmised that, in solution with chloroform-d, compounds 20-25 degrade to
their respective dehalogenated derivatives. It is worth mentioning that, although two
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ketones (acetone and acetophenone) were screened in place of aldehydes (not illustrated in
Table 3), no condensation was observed for either reaction.
Table 3. Formation of ethyl-2-iodo-2-alkenoate

Entry
1
2
3
4
5
6

Aldehyde
R = Et
R = (CH2)2CH3
R = (CH2)4CH3
R = (CH2)5CH3
R = Cyclohexyl
R = CH(CH3)(Ph)

Ethyl 2-iodo-2-alkenoatea,b
20 [R = Et, 96%]
21 [R = (CH2)2CH3, 83%]
22 [R = (CH2)4CH3, 92%]
23 [R = (CH2)5CH3, 61%]
24 [R = Cyclohexyl, 55%]
25 [R = CH(CH3)(Ph), 28%]

a General

conditions for the preparation of iodoalkenoates: 1.25 equiv. N-iodosuccinimide
(NIS), 3.5 equiv. NaH, 1.0 equiv. triethylphosphonoacetate, then 1.0 equiv. aldehyde. See
experimental section for full details.
b Yield of pure product isolated after chromatography.
With compounds 20-25 in hand, Kosugi-Migita-Stille couplings of each compound with
tributyl(2-nitrophenyl)stannane were attempted. Unfortunately, in no case was clean
coupling observed. Rather, results ranged from recovery or decomposition of starting
material to trace amounts of product contaminated with unknown impurities being
obtained. Thus, a different means of access to 2-(2-nitroaryl)alkenoates was sought.
We next attempted to form these alkenoates in a similar fashion as for the production
of compound 10. However, upon reaction of either methyl 2-nitrophenylacetate or ethyl 2nitrophenylacetate with any aldehyde of longer chain length than acetaldehyde, no reaction
was observed. Therefore, we envisioned a third route, this time from 2-nitrobenzaldehyde.
Known α-ketoester 26 was able to be prepared from 2-nitrobenzaldehyde in 4 steps as
reported by Chorev et al.25 Compound 27 was selected as a representative 2-(2nitroaryl)alkenoate for cyclization, and was successfully prepared by a Wittig reaction of 26,
9

albeit in low isolated yield (Scheme 7). Interestingly, compound 10 was not formed under
similar reaction conditions between 26 and ethyltriphenylphosphonium iodide.

Scheme 7. Formation of and attempted cyclizations of precursor 21.
With 27 in hand, cyclizations to N-hydroxyindole 28 and N-methoxyindole 15 under
optimized conditions were attempted. In both cases, no desired product was observed, nor
was the starting material recovered. Instead, it appears that decomposition occurs over the
course of the reaction. Based on several additional failed attempts to cyclize 27 under a
variety of conditions, it was determined that precursors with carbon chains beyond the
butenoate derivatives were unsuitable substrates for this class of cyclization.
The steric and electronic effects of substitution on the aryl ring of the cyclization
precursor were examined next. Six additional methyl 2-(2-nitroaryl)butenoate derivatives
(Table 3, compounds 29-34) were synthesized via a Kosugi-Migita-Stille cross coupling of
substituted 2-nitro-1-bromophenyls with methyl 2-(tributyltin)-2-butenoate.26 All coupling
products were isolated in low to moderate yield as a mixture of E/Z stereoisomers (Scheme
8).
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Scheme 8. Kosugi-Migita-Stille coupling to give 29-34.
Once compounds 29-34 were isolated, each was subjected to optimized cyclization
conditions in an attempt to isolate both the N-hydroxy- and N-methoxyindole derivatives. It
was found that the reaction was highly sensitive to the position of substitution on the
benzene ring. The derivatives substituted with a methoxy group in the 4- and 5-position (3031) yielded their respective N-hydroxy- and N-methoxyindoles in fair to moderate yields
(Table 4 entries 2A-3B). However, the corresponding 3- and 6-methoxy substituted analogs
yielded neither N-hydroxy- nor N-methoxyindole products, and no starting material was
recovered in either case (entries 1A-B and 4A-B). Although it appears that cyclization does
not tolerate steric encumbrance at the latter positions, we currently are unsure of the
reasons for that limitation. Ester-substituted butenoates (33 and 34) also successfully
cyclized to form either the corresponding N-hydroxy- or N-methoxyindole in low to
moderate yields (Table 4, entries 5A-6B). While the desired N-methoxyindoles were
obtained, in three of the examples seen in Table 4 (entries 3-B and 5B-6B), pure samples
could not be isolated, indicating that direct cyclization to N-alkoxyindoles by this method is
not an ideal approach to these products. However, compounds 38 and 40 could be readily
produced in excellent isolated yields by the alkylation of the corresponding Nhydroxyindoles with methyl iodide in the presence of potassium carbonate (Scheme 9).
11

Table 4. Formation of N-hydroxyindoles and N-methoxyindoles from aryl-substituted
precursors.
Entry
Precursor
N-hydroxyindolea
N-methoxyindoleb

1-A
1-B

29 (R = 6-OMe)
29 (R = 6-OMe)

not observed

2-A
2-B

30 (R = 5-OMe)
30 (R = 5-OMe)

35 (R = 5-OMe, 36%)

3-A
3-B

31 (R = 4-OMe)
31 (R = 4-OMe)

37 (R = 6-OMe, 42%)

4-A
4-B

32 (R = 3-OMe)
32 (R = 3-OMe)

not observed

5-A
5-B

33 (R = 5-CO2Me)
33 (R = 5-CO2Me)

39 (R = 5-CO2Me, 29%)

not observed

36 (R = 5-OMe, 60%)

38 (R = 6-OMe, 46%)c

not observed

40 (R = 5-CO2Me, 27%)d

6-A
34 (R = 4-CO2Me)
41 (R = 6-CO2Me, 25%)
6-B
34 (R = 4-CO2Me)
42 (R = 6-CO2Me, 45%)e
a Conditions use for all 1-6-A entries: 2.3 Equiv. sodium tert-pentoxide. See experimental
section for details. Yields are reported as pure isolated compounds after chromatography
unless otherwise noted.
b Conditions use for all 1-6-B entries: 2.3 Equiv. sodium tert-pentoxide, then 3 equiv.
dimethyl sulfate. See experimental section for details. Yields are reported as pure isolated
compounds after chromatography unless otherwise noted.
c Product was isolated with an inseparable impurity. Compound 38 was confirmed by
methylation of 37 as described in Scheme 4.
d Product was isolated with an inseparable impurity. Compound 40 was confirmed by
methylation of 39 as described in Scheme 4.
e Isolated as an inseparable mixture, 14.3:1 ratio of product to starting material. Yield and
ratio determined by 1H NMR.
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Scheme 9. Formation of N-methoxyindoles 38/40 from N-hydroxyindoles 37/39.
The base-mediated transformation reported to afford N-hydroxy- and Nalkoxyindoles can be mechanistically rationalized as illustrated in Scheme 10, and is
supported by a number of related observations described in the literature.15a, 17, 27, 28 First,
the deprotonation of 43 will afford 44 as one of several possible resonance forms. 1,7electrocyclization of 44 would give rise to 45, which can subsequently undergo ring-opening
to furnish nitroso-intermediate 46. 1,5-electrocyclization of 46 is plausible based upon
literature precedence, and would afford intermediate 47. It is then theorized that the loss of
formaldehyde from 47 would drive the formation of 48. Compound 48 should then readily
undergo aromatization to 49. Depending on reaction conditions, 49 could either be
protonated during acidic work-up to yield N-hydroxyindole 50, or react with an added
electrophile to afford N-alkoxyindole 51.
Based upon the mechanism outlined, while the major products formed from the two
pathways are proposed to be either the N-hydroxy- or N-alkoxyindole, in both cases
formaldehyde should also be lost in the conversion of 47 to 48. For all data entries reported
in this chapter, formaldehyde was never observed, presumably due to evaporation during
the removal of solvents.
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Scheme 10. Proposed mechanism for the formation of N-hydroxy- and N-alkoxyindoles.
III.

Conclusion
N-hydroxy- and N-alkoxyindoles can be prepared from a base-mediated cyclization of

2-(2-nitroaryl)-2-butenoate methyl or ethyl esters. N-hydroxyindoles are formed from a
one-step reaction using sodium tert-pentoxide, and N-alkoxyindoles are formed in a twostep, one pot reaction using sodium tert-pentoxide followed by addition of an electrophile.
Cyclization and alkylation using potassium tert-butoxide in tert-butanol can be
accomplished, but the yields from these reactions are highly variable. Additionally, while it
has been shown that cyclization conditions are suitable for an array of 2-(2-nitroaryl)-2butenoates with steric and electronic variety on either the phenyl ring or added electrophile,
alkenoates chains longer than the showcased butenoate are not tolerated. This chemistry
illustrates a novel method for the production of both N-hydroxy- and N-alkoxyindoles.
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Chapter 2—Total syntheses of dilemmaones A and B and progress toward the
synthesis of dilemmaone C
I.

Introduction
In 1997, a variety of specimens were collected off the coast of Cape Town, South Africa

in order to explore the biomedical potential of South African marine invertebrates. A
bioassay-directed fractionation of the crude extract from a mixed collection of sponges led
to the determination of a sphingolipid as the active metabolite. Subsequent 1H NMR and 13C
NMR investigations of the inactive fractions led to the structural elucidation of dilemmaones
A (52), B (53), and C (54) (Figure 2).29 These indole alkaloids obtained their unique familial
name based upon the confusion surrounding their sponge source. However, a process of
elimination suggested that one of the sponges in the mixed collection, Ectyonanchora
flabellata, was the source of the dilemmaones.

Figure 2. Structures of the dilemmaones.
The relatively simple structures of dilemmaones A-C are unusual. To the best of our
knowledge, no other 2-hydroxymethylene- or 2-methoxymethylene-substituted indoles
have been isolated and fully characterized to date. In addition to the unique C2-substituent,
only a few other examples of 6,7-annulated indole natural products have been reported in
the literature. These include the trikentrins, a family of compounds displaying antibacterial
15

activity that were first isolated by Capon et al from the marine sponge Trikentrion
flabelliforme.30 Members of this family of compounds include cis-trikentrin A (55), transtrikentrin A (56), cis-trikentrin B (57), and trans-trikentrin B (58) (Figure 3), along with
several other compounds.

Figure 3. Structures of four trikentrins.
Subsequent to the isolation of the trikentrins, the related trikendiol,31 trikentramine,32 and
trikentramides33 have all been isolated from sponges belonging to the genus Trikentrion. The
structurally similar herbindoles were isolated from Axinella sp., an Australian sponge, by
Scheuer et al.34 Herbindole A (59), herbindole B (60), and herbindole C (61) possess both
cytotoxic and antifeedant properties (Figure 4).

Figure 4. Structures of the herbindoles.
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Two related compounds, monomargine (62) and monomarginine (63), are cytotoxic lactams
isolated from Monocarpia marginalis (Figure 5).35 These tetracyclic compounds possess the
6,7-annulated indanone-like framework characterized by the dilemmaones.

Figure 5. Structures of monomargine and monomarginine.
The uncommon structural framework and interesting biological profiles of the
trikentrins and herbindoles have made them attractive targets for total synthesis. The
challenges associated with the construction of these complex systems are reflected in the
many distinct approaches that have been reported for their racemic and enantioselective
total syntheses. Between 2005-2007, Kerr et al reported the racemic syntheses of herbindole
A (59), herbindole B (60), cis-trikentrin A (55), and cis-trikentrin B (57) utilizing a DielsAlder reaction of quinoid imines.36,37 Previous to those reports, Kanematsu et al reported the
enantioselective synthesis of cis-trikentrin B (57) which featured an intramolecular DielsAlder reaction of an allenic dienamide and stereoselective cleavage of a bicyclic system.38 To
date, there has been no reported synthesis for any member of the dilemmaone family,
despite their skeletal resemblance to the trikentrins and herbindoles. Hence, we envisioned
a route to the dilemmaones showcasing a Watanabe-Cenini-Söderberg cyclization39 as the
key, terminal step. Herein we report the first total syntheses of dilemmaones A and B and
progress toward the synthesis of dilemmaone C.
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II.

Results and Discussion
Retrosynthetically, dilemmaone B (53) can be constructed from the palladium-

catalyzed N-heterocyclization via Watanabe-Cenini-Söderberg cyclization conditions of onitrostyrene 64. Compound 64 can arise from the Kosugi-Migita-Stille cross-coupling
between vinyl stannane 65 and an arylhalide (66). Arylindanone 66 could be fashioned
through the manipulation of commercially-available 2,3-dihydro-5-methylinden-1-one (67).

Scheme 11. Retrosynthetic route to dilemmaone B.
a. Synthesis of Dilemmaone B
Initial work toward dilemmaone B was pioneered by Dr. Christopher Dacko of the
Söderberg lab. 6-Amino-2,3-dihydro-5-methylinden-1-one (68) was prepared in two steps
from commercially available 2,3-dihydro-5-methylinden-1-one (67) as reported by Pinna et
al40 (Scheme 12). As described in Scheme 12, Dr. Dacko originally reported the first
syntheses of compounds 69, 70, and 71. Optimization work for some of these reactions was
done by a number of the undergraduates who worked with me.
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Scheme 12. Initial synthetic approach to dilemmaone B.
In order to install the nitro group present on C7 of the N-heterocyclization precursor 64, a
direct nitration of 68 to intermediate 71 was attempted by Dr. Dacko. Lemaire et al have
reported a one-step nitration of several anilines using 2,3,5,6-tetrabromo-4-methyl-4nitrocyclohexa-2,5-dienone (74)41 as a nitronium ion source.42 Utilizing Lemaire’s reaction
conditions, aniline 68 was seemingly converted to nitroaniline 71. Dr. Dacko confirmed that
electrophilic aromatic substitution had taken place by the presence of only one aromatic
proton by 1H NMR. However, upon HRMS analysis, no molecular ion or protonated molecular
ion was observed for presumed 71. Instead, the HRMS spectrum surprisingly displayed two
peaks of equal intensity at m/z = 240 and 242, indicating the presence of a bromine atom.
Thus, Dr. Dacko determined that aniline 68 was not nitrated, but rather brominated by 74
to give bromoindanone 75 in 59% isolated yield (Scheme 13). Iranpoor and Firouzabadi
have also reported the nitration of aromatic amines using a AgNO3/Br2, PPh3 reagent
system.43 Interestingly, Dr. Dacko’s exposure of aniline 68 to these conditions also produced
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the undesired bromoindanone 75 as the sole reaction product in comparable yield to that
seen when using Lemaire’s conditions.

Scheme 13. Unexpected bromination of aniline 68 as observed by Dr. Dacko.
After the failure of these direct aniline nitration methods, a more traditional route to
o-nitroaniline 71 was envisioned, involving sequential protection, nitration, and
deprotection protocol. Aniline 68 was first reacted with acetyl chloride in the presence of
triethylamine to afford acetanilide 69 in good yield (Scheme 12). Nitration of 69 initially
proved to be problematic. However, after optimization of the reaction conditions, it was
discovered that the most effective and concise procedure was through the use of fuming
HNO3 and concentrated H2SO4 at a reaction temperature of -20 °C for 90 min. Using these
conditions, nitroindanone 70 was furnished in 70% yield. Subsequent deprotection of 70 to
o-nitroaniline 71 was attempted using a procedure reported by Pouli et al.44 While these
conditions did afford nitroaniline 71, yields were inconsistent, with results ranging from 584% isolated yields. It is hypothesized that the wide range of yields are due to the sensitivity
of the free amine present on 71 to fluctuations in pH during both work-up and
chromatography. Conversion of 71 to the corresponding halides also proved challenging.
One pot diazotization and iodination of aromatic amine 71 furnished iodoindanone 72 in
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moderately good yield, but we were unable to prepare the corresponding bromoindanone
from 71 using several variations of similar methodology. Next, Kosugi-Migita-Stille crosscoupling of iodoindanone 72 with (E)-3-(tributylstannyl)-2-propen-1-ol (65) was
attempted. Under all screened sets of conditions, however, the only observed products were
dehalogenated nitroindanone 73 or apparent decomposition of 72. Additionally, a
Sonogashira coupling reaction between 72 and 3-(tert-butyldimethylsiloxy)-1-propyne was
attempted (not pictured), in an attempt to afford cyclization precursor 64 via a sequential
coupling and reduction route. However, those reaction conditions also afforded deiodinated
nitroindanone 73. As iodoindanone 72 was not a good candidate for the access of cyclization
precursor 64, a different approach was envisioned.
The second iteration of the synthesis of dilemmaone B sought to install an aromatic
halogen prior to nitration, thus avoiding the more circuitous route involving a
protection/deprotection protocol. To that end, various conditions were screened in an
attempt to access the desired bromoindanone 76 (Table 5). One pot diazotization and
bromination of aniline 68 proceeded to afford the desired bromoindanone 76 in 75% yield
(Table 5, entry 1). In an effort to directly convert commercially available 2,3-dihydro-5methylinden-1-one (67) to compound 76, thus effectively eliminating the two-step process
to afford 68 (Scheme 12), bromination with Br2/AlCl3 (Table 5, entry 2) was attempted,
however, only the undesired isomer (77) was observed. However, when 67 was subjected
to conditions based upon those previously reported in our laboratory by Dr. Matthew
Cummings,45 both the desired bromoindanone (76) and its regioisomer (77) were obtained
in 32% and 41% isolated yields, respectively (Table 5, entry 3).
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Table 5. Alternate synthetic access to intermediate 76.a,b
Entry

Starting Material

Reagents

1

68

HBr, NaNO2, CuBr

2

67

Br2, AlCl3

3

67

NBSb, H2SO4

Yield 76 (%)

Yield 77 (%)

75
12
32

41

aValues

given are isolated yields. Compounds 76 and 77 are separable by flash column
chromatography.
bNBS

= N-bromosuccinimide.
With 76 in hand, nitration using fuming HNO3 and concentrated H2SO4 was attempted

(Scheme 14). As expected, two isomers were obtained, the desired nitroindanone 79 as the
major product (64% isolated yield) and regioisomer 78 as the minor product (17% isolated
yield). This protocol has allowed for the formation of arylindanone 79 in two steps from a
commercially-available substrate rather than the originally-proposed six steps.
Nitroindanone 79 was then subjected to Kosugi-Migita-Stille cross-coupling with (E)-3(tributylstannyl)-2-propen-1-ol (65). Upon optimization, we were gratified to find that
cyclization precursor 64 could be obtained cleanly in 55% yield. Compound 64 was then
subjected to Watanabe-Cenini-Söderberg reductive cyclization conditions. Despite our
confidence in conversion of 64 to dilemmaone B (53) as expected, disappointingly, the
reaction proved to be unsuccessful. Rather, unreacted starting material (64) was recovered
in all screened sets of conditions for Watanabe-Cenini-Söderberg cyclization.

22

Scheme 14. Second synthetic approach to dilemmaone B.
Theorizing that the electronics of either the indanone ring or free alcohol might be affecting
the cyclization, compound 79 was first converted to o-nitrostyrene derivative 81 via KosugiMigita-Stille

cross-coupling

with

(E)-tributyl(3-methoxy-1-propenyl)stannane

(80)

(Scheme 15). 81 was then subjected to acidic reaction conditions with trimethyl
orthoformate in an effort to synthesize diemethylacetal derivative 82. However, whereas 82
was not observed, the corresponding methoxyindene (83) was obtained in low yield in
addition to 11% isolated starting material (81). Despite this unexpected result, we surmised
that 83 was sufficiently altered in its electronics from compound 64, and thus derivative 83
was subjected to reductive cyclization conditions. Upon examination of the resultant crude
1H

NMR, no indole product (predicted compound 84) was observed. Rather, chemical shifts

indicated that 83 had instead reverted to indanone 81.
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Scheme 15. Synthesis of derivative 83.
Based upon these results, it was determined that it was unlikely that the electronics of the
system were affecting the attempted cyclization. This discovery was not particularly
surprising, as compounds containing unprotected carbonyls such as esters of variety 8546
and precursors to complex compounds such as cimitrypazepine (86) that contain free
alcohols47 have cyclized utilizing Watanabe-Cenini-Soderberg conditions without issue in
our hands (Figure 6).

Figure 6. Two compounds made from reductive cyclizations in the Söderberg lab.
In an effort to effect cyclization by different but related means, both o-nitrostyrene
derivatives that had been synthesized (64 and 81) were subjected to an array of other
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reductive cyclizations. In addition to the originally-attempted Watanabe-Cenini-Söderberg
cyclization

conditions,

TiCl3-promoted

reductive

cyclization,48

diborane-mediated

deoxygenation,49 and a modified Cadogan-Sundberg cyclization50 were screened in the
attempt to convert either 64 or 81 directly to dilemmaone B. In all cases, cyclization to the
desired natural product was never observed. Instead starting material (64 or 81) was
recovered. Upon further examination, we were intrigued to find that sterically-encumbered
o-nitrostyrenes of the type shown in Scheme 16 (non-hydrogen groups on adjacent carbons
to both the nitro and styrene substituents) have not been reported to proceed for any of the
aforementioned reductive cyclizations. This discovery highlights a universal limitation for
reductive N-heterocyclizations of o-nitrostyrenes. Despite not being able to use the desired
Watanabe-Cenini-Söderberg cyclization conditions toward the dilemmaones, we garnered
greater understanding of a reaction that has been widely used in the Söderberg lab since Dr.
James Shriver’s original report in 1997.46

Scheme 16. Sterically encumbered o-nitrostyrenes unable to proceed by reductive
cyclization.
Due to the steric encumbrance of the dilemmaone core being unavoidable, and the proposed
use of our late-stage cyclization of o-nitrostyrene 64 having thus been ruled out as a direct
means of access to dilemmaone B, an alternate pathway was envisioned.
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Compound 64 was transformed into epoxide 89 using 4 equivalents of metachloroperbenzoic acid (m-CPBA). It was anticipated that treatment of 89 with Pd/C and H2
could result in not only reduction of the nitro group to the corresponding amine, but also a
subsequent epoxide ring-opening and elimination to afford the desired product, dilemmaone
B (53). Upon a literature search, to the best of our knowledge, this type of transformation
has only been reported once, and with very limited scope, demonstrated in the example
transformation shown in Scheme 17.51

Scheme 17. The catalytic reduction of 87 reported by Watanabe et al.
Our first attempt of subjecting 34 to conditions similar to Watanabe’s did afford an indole,
however, upon detailed investigation, the 1H NMR chemical shifts were similar but not in
agreement with the shifts reported by Faulkner et al for their structural elucidation of
dilemmaone B. The structure of the isolated product (90) was determined to be the Nhydroxy analog of dilemmaone B (Scheme 18), which presumably arises from incomplete
reduction of the nitro group of 89. Additionally, 46% of unreacted starting epoxide 89 was
isolated.
Encouraged by this result, we examined this one-pot reductive cyclization for its
viability toward the synthesis of dilemmaone B. As our first attempt had yielded 27% of the
N-hydroxy derivative (90) and had not proceeded to completion, we next attempted to run
the reaction at elevated temperature (50 °C, Table 6, entry 2).
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Scheme 18. Synthesis of derivative 90 via sequential epoxidation-reductive cyclization.
In this case, the reaction proceeded to completion, but the only observed product was Nhydroxyindole 90. We next increased the catalyst loading to 5 mol % Pd/C. Upon work-up
and purification, a new product was observed, however, it was found that over-reduction
had occurred, yielding 2,4-dimethylindole derivative 91 as the sole product (Table 6, entry
3). Theorizing that the N-hydroxyindole (90) could be further reduced to the desired indole
at higher catalyst loading, 90 was subjected to reductive conditions with 5 mol % Pd/C. The
progress of this reaction was carefully monitored by TLC. After 2 h, we were excited to
observe that starting material 90 had been completely converted to dilemmaone B (53) in
27% yield, and no over-reduction to 91 was isolated (Table 6, entry 4). In an effort to obtain
dilemmaone B directly from the epoxide precursor, we chose to screen the reducing agent
originally used by Watanabe et al. Upon subjecting 89 to reduction with 2 mol % PtO2 at 50
°C, and again carefully monitoring the reaction progress by TLC, we were gratified to find
that dilemmaone B was indeed obtained in 48% isolated yield after 3 h, and neither Nhydroxyindole 90 nor 2,5-dimethylindole 91 were observed (Table 6, entry 5). It is worth
noting that, while the identities of N-hydroxyindole 90 and dilemmaone B (53) can be
confirmed and differentiated via 1H NMR analysis in CDCl3, solubility of both compounds in
CDCl3 is minimal. Because of this, splitting patterns in that solvent are unclear. However,
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both 90 and 53 are readily solubilized in DMSO-d6. Interestingly, in contrast to their 1H NMR
spectral data in CDCl3, chemical shifts in DMSO-d6 are nearly identical, necessitating
structural confirmation by 1H-15N gHSQC analysis (see Chapter 4 and appendix for details).
Notably, Faulkner et al did not report all resonances for 13C NMR analysis of dilemmaone B,
and thus did not provide detailed characterization (HMBC and NOESY) as they had for
dilemmaone A. Therefore, full NMR analysis was performed for dilemmaone B in DMSO-d6,
and all data for this compound can be found in Chapter 4 (experimental section) and the
appendix.
Table 6. Cyclizations to dilemmaone B.a
Entry SM

Catalyst

Time

Yield 53 (%) Yield 90 (%) Yield 91 (%)

1b

89

2 mol % Pd/C

16 h

27c

2

89

2 mol % Pd/C

16 h

37

3

89

5 mol % Pd/C

16 h

4

90

5 mol % Pd/C

2h

27

5

89

2 mol % PtO2

3h

48

16

aAll

reactions were run in EtOH under 40 psi H2 at 50 °C unless otherwise noted. Yields
reported are isolated yields after chromatography. See experimental section for details.
bReaction
cAlso

run at ambient temperature.

isolated was 46% unreacted starting material 89.
b. Synthesis of Dilemmaone A
With the dilemmaone B successfully synthesized, we turned our attention to the

synthesis of dilemmaone A (52), which differs in structure from dilemmaone B only at the
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C2 position (dilemmaone A possesses a 2-methoxymethyl whereas dilemmaone B has a 2hydroxymethyl substituent). With Kosugi-Migita-Stille coupling adduct 81 in hand (Scheme
19), epoxidation proceeded smoothly to furnish compound 92 as expected in 51% yield.
Cyclization precursor 92 was then subjected to reductive conditions using both Pd/C and
PtO2.

Scheme 19. Synthesis of dilemmaone A.
While we expected to observe similar results for the reduction of 82 when utilizing 2 mol %
Pd/C, as for the conversion of 89 to 90 (synthesis of dilemmaone B), interestingly, both
screened sets of conditions afforded clean conversion of epoxide 92 to dilemmaone A (52).
While 2 mol % Pd/C consistently led to the production of N-hydroxyindole 90 while
attempting to form dilemmaone B, the same conditions fully reduced precursor 92 to
dilemmaone A, and its corresponding N-hydroxyindole was never observed. While the use
of PtO2 worked cleanly toward the production of both dilemmaones A and B, it seems that
the use of Pd/C is marginally more effective for the reduction of epoxide 92. Notably,
dilemmaone A (52) is readily soluble in CDCl3, and 1H NMR chemical shifts match the data
reported by Faulkner et al. A complete analysis of this natural product can be found in the
experimental section and appendix.
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c. Progress Toward the Synthesis of Dilemmaone C
With the successful synthesis of dilemmaones A and B accomplished, we turned our
attention to the synthesis of dilemmaone C. Structurally, the core of dilemmaone C is nearly
identical to that of dilemmaone A, however, dilemmaone C is the only member of the family
of compounds that possesses aromatic substitution at C5. Retrosynthetically, we envisioned
that dilemmaone C could be prepared from compound 93 (Scheme 20), which in turn could
arise from Kotsugi-Migita-Stille coupling of 94 with 80. This divergent approach was
selected, as 78 is one of the two isomers formed in the nitration reaction of 76, thus allowing
for the utilization of both isomers across the syntheses of the dilemmaones.

Scheme 20. Retrosynthesis of dilemmaone C.
With this approach in mind, compound 78 was subjected to reductive conditions and
aniline derivative 95 was obtained in 79% yield (Scheme 21). Subsequently, sequential
diazotization and hydrolysis of compound 95 was performed, and after optimization of the
work-up, phenol 96 was obtained in 38% yield. Nitration of 96 was also successful in
affording 97, albeit in low yield. Further, this transformation has proven to be inconsistent
in its results, and studies toward a reliable method of nitration are ongoing. With the
coupling partner in hand, Kotsugi-Migita-Stille coupling was attempted on compound 97
with 80 under the same conditions used in the synthesis of dilemmaone A. Upon analysis of
the crude 1H NMR, it appeared that coupling had taken place, as characteristic peaks between
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5-7 ppm were observed. However, when purification was attempted, no product was
isolated, presumably due to the small (under 10 mg) scale on which the reaction had been
run.

Scheme 21. Attempted synthesis of compound 98.
It is believed that, pending successful synthesis of o-nitrostyrene 98, dilemmaone C
could be synthesized in the same manner as for dilemmaone A (Scheme 22).

Scheme 22. Proposed future steps toward dilemmaone C.
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Compound 98 should undergo epoxidation to form 99, which should subsequently undergo
one-pot reduction and cyclization to form the desired indole. These proposed steps are the
same as for dilemmaones A and B, thus, it is hypothesized that dilemmaone C can be accessed
with relative ease.
III.

Conclusion
The first total syntheses of the naturally occurring tricyclic indole alkaloids,

dilemmaones A and B, has been successfully accomplished. These compounds can be
efficiently prepared from 2,3-dihydro-5-methylinden-1-one (67), with both syntheses
featuring a Kosugi-Migita-Stille coupling and an interesting one-pot reductive cyclization
using H2 and either a Pd/C or PtO2. As the scope of this reductive cyclization using either
Pd/C or PtO2 has not yet been widely explored, studies are ongoing in our laboratory to
determine its versatility. Dilemmaone B (53) was synthesized in 5 steps (overall yield =
4.0%). From common intermediate 6-Bromo-2,3-dihydro-5-methyl-7-nitroinden-1-one
(79), dilemmaone A (52) was then synthesized in 3 additional steps (overall yield = 12.2%).
Work toward the synthesis of dilemmaone C (54), the most highly-substituted member of
this family of compounds, has begun, and the initial promising results suggest that future
efforts could lead to its production using a related approach.
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Chapter 3—Additional methodological and synthetic work toward indole derivatives
In addition to the projects discussed in chapters 1 and 2, I have worked on a number
of additional side-projects. The first of these was a methodology screening for an efficient
means of access to o-nitrostyrenes that could be subsequently subjected to WatanabeCenini-Söderberg cyclization reactions. The second involved efforts toward the synthesis of
the naturally occurring marinoquinolines, and was pioneered by two undergraduate
students under my supervision. The third was a collaborative effort with the West Virginia
University Division of Forestry and Natural Resources, wherein an exploration of an azidealkyne cycloaddition using lignocellulosic materials as a scaffold for copper nanoparticle
catalysis was performed (not discussed in this report).
I.

Access of substituted o-nitrostyrene derivatives via regioselective MizorokiHeck reactions
a. Introduction
One of the major reactions that has been used over the last two decades by the

Söderberg lab is the Watanabe-Cenini-Söderberg cyclization.39 This reaction, as illustrated
in previous chapters, involves the palladium-catalyzed reductive cyclization of onitrostyrene derivatives to afford indoles. The production of these cyclization precursors can
be accomplished via a vast range of methodologies, including Wittig reactions,52 Suzuki53 and
Stille54 cross-couplings, and others. An additional reaction that has been widely applied to
the synthesis of o-nitrostyrenes and related compounds is the Heck reaction.55 Traditionally,
this reaction involves the reaction of an unsaturated halide or triflate with an alkene in the
presence of a palladium catalyst and base to afford an array of substituted alkenes. Despite

33

its versatility, the Heck reaction is often limited by preference for coordination with the
terminal olefinic carbon. While exploring the literature during work on my original research
proposal, I happened upon a modified Mizoroki-Heck reaction reported by Qin et al, wherein
the opposite substitution preference was observed. As illustrated in Scheme 23, when aryl
triflate 100 was reacted with 3-buten-1-ol (101) under modified Heck conditions, there was
high selectivity for the formation of geminal alkene 102 over its corresponding vicinal
isomer, 103.

Scheme 23. Modified Mizoroki-Heck reaction as reported by Qin et al.
This reactivity was intriguing, as we surmised that it could be applied sequentially,
preceding a Watanabe-Cenini-Söderberg reaction, to afford indoles with substitution at C3.
Although there are numerous methods for the production of 3-substituted indoles, this
would allow for the pre-installation of a substituent at C3 and late-stage cyclization to afford
the indole. This is in contrast to many of the current methodologies, which rely on
substitution at the C3 position of an existing indole.57 This approach additionally could
contribute to the synthetic field, as there are numerous naturally-occurring compounds that
exhibit C3-substitution of an indole core. For example, the structurally diverse tryptamines
are a class of monoamine alkaloids an array of neurological and psychedelic effects.
Tryptamine (104) has been synthesized via the Abramovitch-Shapiro tryptamine synthesis
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(Scheme 24), which is one such example of desired C3-substitution being introduced after
the indole core has been created.58

Scheme 24. Abramovitch-Shapiro tryptamine synthesis.
In an effort to probe the versatility of this modified and regioselective Mizoroki-Heck
reaction, we endeavored to screen its applicability toward the production of o-nitrostyrenes,
particularly those with pre-installed C3 substitution. Here, we report the initial findings of
this study.
b. Results and Discussion
To initiate our screening of the regioselective Mizoroki-Heck conditions applied to
nitroaryl triflates, we selected a simple nitroaryltriflate precursor (2-nitrophenyl
trifluoromethanesulfonate, 105) and subjected it to the reaction conditions reported by Qin
et al.

Scheme 25. Reaction of 105 under modified Mizoroki-Heck conditions.
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We were gratified to find that the desired regioisomer, 106, was formed as the major isomer
in an inseparable mixture with Heck product, 107, in a 6.8:1 ratio and 46% yield (Scheme
25). Despite attempting this reaction under a variety of conditions, including different
solvents, altered catalyst loading, and elevated temperatures, the yields and regioselectivity
remained comparable or depressed from the originally observed values as shown in Scheme
25. Interestingly, when the reaction was run under the same conditions, but with the
temperature increased to 105 °C, the yield and selectivity remained almost identical (47%
and 6.3:1, respectively), an additional product, o-nitrophenol, was also isolated in 11% yield.
This suggests that the reaction can be prone to de-triflation under certain conditions, such
as elevated temperature. Although the results that we obtained were not as promising as
reported in the literature examples, we were nevertheless encouraged by these preliminary
findings. Additionally, upon further perusal of Qin’s results, it was discovered that each
triflate/alkene combination appeared to be specifically tailored to one of several ferrocenebased

ligands.

We

chose

to

screen

our

reactions

with

only

1,1’-

bis(diphenylphosphino)ferrocene (dppf), which could be a contributing factor to our
moderately lower yields.
With our initial findings proving to be a promising lead, we subsequently subjected a
number of other aryltriflates to the same conditions. We first sought to confirm the
preference of the reaction for coupling at the triflate-carbon. To that end, we subjected two
substrates previously made in our lab by Dr. Ansari59 to the Mizoroki-Heck conditions at 105
°C (Scheme 26). The elevated temperature was found to be necessary with our selected set
of reagents in order to avoid recovery of only starting materials. While we did observe the
formation of the desired geminal alkenes from both substrates 108 and 109, the yields were
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very poor (7% of 110 and 7% of 112, respectively). Additionally, for substrate 109, as for
the reaction of 105 with 3-buten-1-ol at elevated temperature, we observed the formation
of the corresponding phenol (113) in 52% yield.

Scheme 26. Reaction of bromonitroaryl triflates under Mizoroki-Heck conditions.
While the initial results for these substrates were poor, nevertheless, we were encouraged
to find that coupling still proceeded, presumably with higher affinity for reaction with the
aryl-triflate carbon.
An additional set of compounds that we attempted Mizoroki-Heck coupling on were
precursors to two natural products, the tetracyclic indole alkaloids ht-13-A (114) and ht-13B (115) (Figure 7).

Figure 7. Structures of indole alkaloids 114 and 115.
The screened precursors, 116 and 118 (Scheme 27) were originally made by Dr. Jeremiah
Hubbard in his efforts to synthesize ht-13-A and ht-13-B. Although the route that these
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precursors were made for ultimately proved unsuccessful, and an alternate pathway led to
the production of the natural compounds,60.61 it was hypothesized that if intramolecular
coupling using Mizoroki-Heck conditions were successful, it could alleviate some of the
difficulties faced by Drs. Hubbard and Zhang, and allow for a more efficient means of access
to these compounds and others of similar molecular structure.

Scheme 27. Attempted Mizoroki-Heck couplings of 116 and 118.
Upon subjecting 116 and 118 to coupling conditions, it was found that neither of the
attempted intramolecular Mizoroki-Heck reactions successfully formed 117 or 119,
respectively. Rather, examination of the crude 1H NMR spectra indicated that no reaction had
taken place, and only shifts for the starting materials were observed. Despite these reactions
not progressing forward as desired, it did serve to reinforce that this methodology appears
to be highly selective for reaction with aryl triflates, whereas aryl halides seem to be
unreactive.
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Finally, three additional cyclization precursors were made utilizing this methodology.
First, known 2-aryl-1-octene 120 was synthesized as reported by Qin et al (Scheme 28).56
Although 120 was successfully made when utilizing the same reaction conditions as
reported, in our hands, the reaction yielded only 37% of the desired compound, whereas a
yield of 83% was reported in the literature. Although we are unsure of the reasons for this
disparity, it may be that unknown variances in conditions from their reports to ours could
be a contributing factor to the overall poor to moderate yields seen for all substrates we have
screened using this chemistry.

Scheme 28. Synthesis of o-nitrostyrene derivative 120.
The second and third cyclization precursors were made in the reaction of nitroaryl triflate
105 with coupling partner 121 to screen for the potential of access to tryptophan derivatives
(Scheme 29).

Scheme 29. Reaction of 105 with amino acid derivative 121.
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Upon subjection to coupling conditions, we observed an inseparable mixture of desired
compound 122 and its regioisomer 123 (32%, 3.1:1 mixture of 122:123) and 19%
unreacted starting material. The yields and regioselectivity for this inseparable mixture of
the three compounds were determined by 1H NMR.
Table 7. Formation of indoles from o-nitrostyrenes made using Mizoroki-Heck reactions.
Entry

Substrate

Conditionsa

Product

Yieldb

1

106

Method A

124, 74%

2

112

Method A

125, 0%

3

120

Method B

126, 37%c

4

122, 123d

Method C

127, 22%

128, 10%
aMethod

A: Pd(OAc)2, PPh3, MeOH/DMF, CO (90 psi), 60 °C, 24 h; Method B: Pd(OAc)2, PPh3,
CH3CN, CO (90 psi), 100 °C, 24 h; Method C: Pd(dba)2, dppp, 1,10-phen., DMF, CO (90 psi),
120 °C, 48 h. See experimental section for details.
bValues
cAlso

reported are isolated yields after purification by chromatography.

isolated was 13% unreacted 120.

dInseparable

reaction.

mixture of 122 and 123 as reported in Scheme 29 was subjected to the
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With an assortment of o-nitrostyrene derivatives formed as described above, each
was subjected to Watanabe-Cenini-Söderberg cyclization conditions. The results for these
reactions are illustrated in Table 7. Compounds 106 and 120 cyclized as expected, affording
their respective indole derivatives (124 and 126) in moderate to good yields (Table 7,
entries 1 and 3). Interestingly, indole 125 was not observed (Table 7, entry 2). It is possible
that this reaction could be promoted using altered Watanabe-Cenini-Söderberg conditions,
although only the listed conditions were screened in this preliminary investigation. Finally,
when the mixed sample of 122 and 123 was subjected to reductive cyclization conditions
(Table 7, entry 4), we were gratified to find that both expected cyclization products (127 and
128) were isolated. In particular, this illustrates a promising method of forming tryptophan
derivatives such as 127 in an expedient fashion.
c. Conclusion
Preliminary work on the applicability of modified Mizoroki-Heck chemistry has been
performed, and initial results suggest that while this is a possible method for the production
of indoles with pre-installed C3 substitution, further optimization is needed. This is
particularly needed for the first, Mizoroki-Heck coupling, reaction in the sequence, as yields
for the resultant o-nitrostyrenes were consistently observed in the poor-to-moderate range.
It is believed that further screening of reaction conditions, particularly focused on the ligand
used, could enhance the yields and regioselectivity of these reactions. A number of indoles
were also synthesized using this two-step pathway. This is highlighted by the production of
tryptophan derivative, 127, and suggests that this methodology may hold promise as a
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means of producing other tryptophan derivatives, which are valuable synthetic building
blocks.
II.

Progress toward the syntheses of the marinoquinolines
a. Introduction
In 2011, six compounds were isolated from a marine gliding bacteria, Ohtaekwangia

kribbensis (strain PWU 25) off the coast of Korea.62 Upon analysis, it was found that one of
these compounds was marinoquinoline A (129), which has previously been isolated from a
marine bacterium, Rapidithrix thanilandica,63 and was determined to act as an acetylcholine
esterase inhibitor.64 Along with marinoquinoline A, five novel additional compounds were
isolated from O. kribbensis: marinoquinolines B-F (130-134), whose structures were
elucidated using a series of 1D and 2D NMR techniques (Figure 8).

Figure 8. Structures of marinoquinolines A-F.
Although the marinoquinolines have only weak activity against a panel of bacteria
and fungi and modest antiprotozoal activity, they are nevertheless structurally interesting
and further studies of them and potential structural analogs merit examination. This is
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highlighted by the variety of methods used to synthesize various members of the
marinoquinoline family. These approaches have used key steps such as a Bronstad-acidmediated arene-ynamide cyclization,65 a palladium-catalyzed cyclization of imines,66 a
palladium-catalyzed Ullmann cross-coupling,67 and an interesting divergent synthetic
approach.68 The first concise syntheses of marinoquinolines A-C was accomplished using a
Morgen-Walls reaction to assemble the quinoline ring by Yao et al in 2012.69
We hypothesized that the marinoquinoles could be synthesized using a Henry
reaction and modified Watanabe-Cenini-Söderberg cyclizations as the key steps in a novel
and concise approach. This work was largely performed by two of the summer
undergraduate students who worked under my supervision in the Söderberg lab. Herein are
presented preliminary results toward the syntheses of these interesting tricyclic alkaloids.
b. Results and Discussion
In an attempt to ascertain proof-of-concept, we first endeavored to create the nonsubstituted marinoquinoline core, 135. Retrosynthetically, we envisioned that 135 could be
formed from the cyclization of nitrostyrene 136, which could in turn be constructed from
the Henry reaction of 137. Aldehyde 137 could be obtained from 138, which could be
cyclized using a palladium-catalyzed N-heterocyclization as reported by Dr. Banini17 from
139. Compound 139 could be obtained by the condensation of commercially available 2nitrophenylacetonitrile (140). With these transformations thus proposed, we set out to
make the marinoquinoline core (135), and pending its success, to synthesize the
marinoquinolines utilizing similar protocol.
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Scheme 30. Retrosynthesis of the marinoquinoline core.
We first sought to accomplish the condensation of 2-nitrophenylacetonitrile (140)
with acetaldehyde in the hopes of obtaining compound 139. Upon reaction utilizing similar
conditions as for the construction of cyclization precursor 10 (Chapter 1), we were initially
discouraged, as there was no evidence of the expected olefinic quartet in the 1H NMR
spectrum. However, upon further investigation, we found that instead of the reaction ceasing
at the production of 139, spontaneous cyclization had occurred to afford 4quinolinecarbonitrile-N-oxide (141) in 47% yield (Scheme 31).

Scheme 31. Unexpected formation of N-oxide 141.
Despite this unexpected product and its modest yield, we were encouraged by the result, as
this set of conditions negated the need for a two-step condensation and sequential
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cyclization pathway as originally envisioned. Additionally, when compared to the related
condensations that have been performed (as described in Chapter 1), the yields here are
higher for the equivalent of a two-step process than for the single condensation. We then
queried whether this reaction required the addition of 18-crown-6 in order to occur. Thus,
we screened the reaction of compound 140 as before, changing the conditions only by
omitting the addition of the crown ether. Compound 141 was gratifyingly once again
obtained, interestingly, in elevated yield (66%, Scheme 31).
Encouraged

by

these

results,

we

next

attempted

to

form

the

three

quinolinecarbonitrile-N-oxides that could act as precursors to marinoquinolines A-C using
similar methodology (Scheme 32).

Scheme 32. Attempted formation of compounds 142, 143, and 144.
Unfortunately, when substituting any aldehyde for acetaldehyde, none of the cyclization
products (142-144) were observed, nor were condensation products that are derivatives of
139 (seen in Scheme 30). Instead, in all cases, whether the reaction was run with or without
18-crown-6, degradation of the starting material appeared to have occurred. Although
obtaining quinolinecarbonitrile-N-oxides 142-144 via this reaction would have been a facile
and direct method, it was noted that these negative results were consistent with what was
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observed when attempting to form 2-(2-nitroaryl)alkenoates via similar means (Chapter 1),
in that any aldehyde of longer chain length than formaldehyde or acetaldehyde would not
undergo condensation.
Despite the lack of success in forming substituted quinolinecarbonitrile-N-oxides
directly from 2-nitrophenylacetonitrile, we hypothesized that they could instead be
produced from the subjection of unsubstituted quinolinecarbonitrile-N-oxide 141 to
reaction with Grignard reagents. Further, we expected that when exposed to the reaction
conditions necessary to facilitate substitution, the N-oxide would reduce to the quinoline.
Thus, compound 141 was screened for reactivity with three Grignard reagents in the
attempt to form the corresponding 2-substituted quinoline derivatives (Scheme 33).

Scheme 33. Reaction of 141 with Grignard reagents to form 145-147.
After screening a variety of methods of reaction, it was found that either using commerciallypurchased and anhydrous Grignard reagents or formation of Grignard reagents in situ
followed by their direct addition to 141 afforded compounds 145-147 in a wide range of
yields. Methyl-substituted quinoline 145 was obtained in good yield, however, compounds
146 and 147 were formed in 17% and 2% yields, respectively, and in both cases unreacted
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starting material was obtained in significant quantities (20% and 44% recovered,
respectively).
With compounds 145-147 in hand, we next attempted to convert the cyano-group to
an aldehyde in preparation for the subsequent Henry reaction. However, when compound
145 was subjected to reaction with diisobutylaluminum hydride (DIBAL-H), reduction to the
corresponding aldehyde was never observed under any screened conditions (Scheme 34).
Instead, in all cases, starting material (145) was recovered.

Scheme 34. Attempted reduction of 145.
We next attempted to access aldehyde 148 by an alternate pathway. By subjecting
compound 145 to hydrolysis conditions with H2SO4 and H2O, we hoped to obtain the
corresponding carboxylic acid, which we theorized could be subsequently reduced to obtain
148. However, upon analysis of the presumed acid, while most of the observed 1H NMR
peaks were in agreement with literature values, not all matched.70 Additionally, our
experimental melting point was not in agreement with the literature value of 244 °C. Due to
these inconclusive data, as well as difficulties encountered while attempting to produce
aldehyde 148, additional work is needed in order to further the research toward the
production of the marinoquinolines.
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c. Conclusion
Initial progress has been made toward the syntheses of marinoquinolines A-C. This
work

has

showcased

an

unexpected

one-pot

condensation/cyclization

of

2-

nitrophenylacetonitrile to form quinolinecarbonitrile-N-oxide that can be accomplished
with or without the use of a crown ether. Although 2-substituted quinolinecarbonitrile-Noxides

cannot

be

formed

by

this

one-pot

methodology,

the

respective

2-

alkylquinolinecarbonitriles can be formed from the reaction of quinolinecarbonitrile-Noxide with a Grignard reagent in poor to good yields. Thus far, the reduction of the cyanogroup to the corresponding aldehyde has proven to be difficult. Future work may necessitate
the Henry reaction of an aldehyde prior to installation of substitution at the 2-position in
order to avoid these unprecedentedly difficult reductions if an alternate means of access to
the aldehydes cannot be accomplished. Upon successful Henry reactions to the nitrostyrenes
of variety 136, it is believed that a palladium-catalyzed reductive N-heterocyclization will be
successful in affording the marinoquinolines.
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Chapter 4—Experimental Methods
I.

General Procedures
All NMR spectra were recorded in either CDCl3 or DMSO-d6 at 400 MHz (1H-NMR) and

100 MHz (13C-NMR) or 600 MHz(1H-NMR) and 150 MHz (13C-NMR) at ambient temperatures
unless otherwise stated. The chemical shifts are expressed in δ values relative to SiMe4 (0.0
ppm, 1H and

13C)

or CDCl3 (77.0 ppm,

13C)

internal standards. The multiplicity of each

resonance observed in the 1H NMR spectra are reported as, s = singlet; d = doublet; t = triplet;
q = quartet; m = multiplet. HRMS data were obtained via electrospray ionization (ESI) with
an ion trap mass analyzer. Solvents (tetrahydrofuran, dichloromethane, and toluene) were
purified and dried prior to use via two consecutive columns composed of activated alumina
and Q5 catalyst on a Glass Contours solvent purification system. Anhydrous N,Ndimethylformamide and anhydrous N,N-dimethylacetamide were used as received. Hexanes,
ethyl acetate, and 1,4-dioxane were distilled from calcium hydride. Chemicals prepared
according to literature procedures have been referenced the first time used. All other
reagents were obtained from commercial sources and used as received. Reactions were
performed under a nitrogen atmosphere in oven-dried glassware unless otherwise noted.
Solvents were removed from reaction mixtures and products on a rotary evaporator at water
aspirator pressure unless otherwise stated. Melting points (uncorrected) were recorded
from pure products obtained by chromatography.
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II.

Experimental

Ethyl 2-(2-nitrophenyl)-2-butenoate (10). Ethyl 2-(2-nitrophenyl)acetate
(740 mg, 3.60 mmol) and 18-crown-6 (240 mg, 0.90 mmol) were combined in a roundbottomed flask and the system was purged with N2. THF (9 mL) was added and the solution
was cooled to -78 °C. A suspension of t-BuOK (440 mg, 3.90 mmol) in THF (6 mL) was added
dropwise via syringe and solution immediately turned deep blue. Acetaldehyde (1.0 mL, 17.9
mmol) was added in one portion via syringe, and the resulting solution was stirred at -78 °C
for 30 min, then warmed to ambient temperature and stirred for 16 h. The reaction was
quenched by slow addition of saturated aqueous NH4Cl and extracted with EtOAc (3 x 15
mL). The combined organic phases were dried (MgSO4), and the solvent was removed under
reduced pressure. The resulting residue was purified by chromatography (hexane/EtOAc
9:1 then 7:3) to afford 10 (246 mg, 1.05 mmol, 29%) as a yellow oil as a mixture of
stereoisomers (major/minor = 33.3:1 by 1H NMR). Analytical data from the 33.3:1 mixture
of stereoisomers: 1H NMR (major isomer) δ 8.14 (dd, J=8.2, 1.2 Hz, 1H), 7.65 (td, J=7.5, 1.3
Hz, 1H), 7.56-7.49 (m, 1H), 7.27 (dd, J = 7.6, 1.4 Hz, 1H), 7.22 (q, J = 7.2 Hz, 1H), 4.15 (m, 2H),
1.73 (d, J = 7.2 Hz, 2H), 1.20 (t, J = 7.1 Hz, 3H); 1H NMR (minor isomer, partial data) δ 8.06
(dd, J = 8.1, 1.2 Hz, 1H), 7.34 (dd, J = 7.6, 1.4 Hz, 1H), 6.41 (q, J = 7.3 Hz, 1H), 2.30 (d, J = 7.3
Hz, 3H);

13C

NMR (major isomer) δ 165.5, 148.7, 139.6, 133.3, 132.8, 132.6, 131.1, 129.0,

124.9, 61.2, 15.6, 14.2; 13C NMR (minor isomer, partial data) δ 142.8, 133.6, 132.7, 128.7,
124.5, 60.7, 16.3, 14.1; IR (ATR) 2982, 1709, 1523, 1345, 1267, 1241, 1188, 1047, 1035 cm 1;

HRMS (ESI) calculated for C12H14NO4 (M+H+) 236.0917; found, 236.0930.
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Ethyl 1-methoxyindole-3-carboxylate (12). Method A: A solution of 10 (181
mg, 0.77 mmol) in t-BuOH (2 mL) was added slowly to a pre-formed solution of t-BuOK (1.01
g, 8.16 mmol) in t-BuOH (3 mL) under a nitrogen atmosphere. The mixture was cooled in an
ice bath for 10 min. MeI (170 μL, 1.10 mmol) was added drop-wise over a period of 2 min.
The solution was allowed to warm to ambient temperature and stirred for 3 h. The reaction
was quenched with a solution of saturated NH4Cl (aqueous, 10 mL) and extracted with
dichloromethane (3 x 10 mL). The combined organic phases were washed with H 2O (3 x 10
mL) and dried (MgSO4). Solvents were removed under reduced pressure to obtain 12 (141
mg, 0.65 mmol, 84%) without further purification as a pale yellow oil.
Method B: Compound 10 (128 mg, 0.54 mmol) was added to a round-bottomed flask, and the
system was purged with nitrogen gas. Anhydrous PhMe (6 mL) was added via syringe, and
the solution was cooled to 0 oC. Sodium tert-pentoxide (40% solution in PhMe, 380 L, 1.24
mmol) was added drop wise, and the solution immediately turned purple then red. The
solution was stirred at 0 oC for 10 min and dimethyl sulfate (150 L, 1.62 mmol) was added
via syringe. Solution was warmed to ambient temperature and stirred for 3 h. The resulting
mixture was quenched with saturated aqueous ammonium chloride and extracted with
EtOAc (3 x 10 mL). The combined organic phases were dried (MgSO4) and the solvent was
removed under reduced pressure. The residue was purified by chromatography
(hexane/EtOAc, 7:3) to afford 12 (64 mg, 0.29 mmol, 54%) as a pale yellow oil. 1H NMR δ
8.18 (d, J=7.8 Hz, 1H), 7.96 (s, 1H), 7.45 (dd, J=7.8, 1.2 Hz, 1H), 7.32-7.27 (m, 2H), 4.38 (q,
J=7.2 Hz, 2H), 4.13 (s, 3H), 1.41 (t, J=7.2 Hz, 3H); 13C NMR δ 164.6, 132.0, 128.3, 123.4, 122.8,
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122.3, 121.8, 108.5, 103.7, 66.6, 59.8, 14.5; IR (ATR) 3118, 2906, 2831, 1686, 1514, 1224,
1023, 772 cm-1; HRMS (ESI) calculated for C12H14NO3 (M+H+) 220.0968; found, 220.0968.

Ethyl 1-benzyloxyindole-3-carboxylate (13). Treatment of 10 (169 mg,
0.72 mmol) in t-BuOH (3 mL) with t-BuOK (1.01 g, 8.16 mmol) in t-BuOH (3 mL) followed by
the addition of benzyl bromide (180 μL, 1.08 mmol), as described for 12 (ambient
temperature, 3 h), gave after work up but without chromatographic purification 13 (166 mg,
0.56 mmol, 78%) as a pale yellow oil. 1H NMR δ 8.17 (dt, J=7.8, 1.2 Hz, 1H), 7.71 (s, 1H), 7.407.24 (m, 8H), 5.21 (s, 2H), 4.35 (q, J=7.2 Hz, 2H), 1.39 (t, J=7.2 Hz, 3H); 13C NMR δ 164.6, 133.8,
132.5, 129.6, 129.5, 129.4, 128.8, 123.3, 122.7, 122.3, 121.7, 108.8, 103.4, 81.0, 59.8, 14.5; IR
(ATR) 3123, 2947, 1698, 1521, 1204, 1082, 740 cm-1; HRMS (ESI) calculated for C18H18NO3
(M+H+) 296.1287; found, 296.1289.

Methyl 1-(2-propen-1-yloxy)indole-3-carboxylate (14). Treatment of
1119 (94 mg, 0.43 mmol) in t-BuOH (2 mL) with t-BuOK (600 mg, 4.90 mmol) in t-BuOH (3
mL) followed by 3-bromo-1-propene (110 μL, 0.65 mmol), as described for 12 (ambient
temperature, 3 h), gave after chromatography (hexanes/EtOAc, 9:1), 14 (91 mg, 0.39 mmol,
91%) as a pale yellow oil. 1H NMR δ 8.16 (d, J=7.8 Hz, 1H), 7.92 (s, 1H), 7.46 (d, J=8.1 Hz, 1H),
7.31 (dd, J=7.5, 1.2 Hz, 1H), 7.27 (dt, J=8.0, 1.2 Hz, 1H), 6.10 (ddt, J=17.0, 10.2, 6.6 Hz, 1H),
5.37 (dd, J=10.2, 0.9 Hz, 1H), 5.33 (dq, J=17.1, 1.2 Hz, 1H), 4.74 (dt, J=7.2, 1.2 Hz, 2H), 3.91 (s,
3H); 13C NMR δ 165.0, 132.6, 130.7, 129.5, 123.3, 122.8, 122.4, 121.7, 108.9, 103.1, 79.7, 51.1;
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IR (ATR) 3126, 2981, 2940, 1693, 1520, 1200, 1081, 1030, 740 cm-1; HRMS (ESI) calculated
for C13H14NO3 (M+H+) 232.0968; found, 232.0968.

Methyl 1-methoxyindole-3-carboxylate (15). Treatment of 11 (176 mg,
0.80 mmol) in t-BuOH (3 mL) with t-BuOK (1.01 g, 8.16 mmol) in t-BuOH (3 mL) followed by
addition of MeI (200 μL, 1.20 mmol), as described for 12 (ambient temperature, 3 h), gave
after work up but without chromatographic purification 1 (121 mg, 0.59 mmol, 74%) as a
pale yellow oil. 1H NMR δ 8.18 (dt, J=7.8, 1.2 Hz, 1H), 7.96 (s, 1H), 7.46 (dt, J=7.8, 1.2 Hz, 1H),
7.33-7.26 (m, 2H), 4.14 (s, 3H), 3.91 (s, 3H);

13C

NMR δ 165.0, 132.0, 128.3, 123.4, 122.8,

122.4, 121.8, 108.6, 103.4, 66.6, 51.1.

Ethyl 1-acetoxyindole-3-carboxylate (17). Compound 10 (106 mg, 0.45
mmol) was added to a round-bottomed flask, and the system was purged with N2. Anhydrous
PhMe (5 mL) was added via syringe, and the solution and cooled to 0 °C. Sodium tertpentoxide (40% solution in PhMe, 310 μL, 1.04 mmol) was added drop wise, and the solution
immediately turned purple then red. This solution stirred at 0 °C for 10 min and acetic
anhydride (130 μL, 1.35 mmol) was added via syringe. Solution was warmed to ambient
temperature and stirred for 3 h. The resultant mixture was quenched by addition of
saturated aqueous ammonium chloride and extracted with EtOAc (3x10 mL). The combined
organics were dried (MgSO4) and the solvent was removed under reduced pressure. The
resulting residue was purified by chromatography (hexane/EtOAc 7:3) to afford 17 (53 mg,
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0.21 mmol, 48%) as an orange oil. 1H NMR δ 8.23-8.17 (m, 1H), 7.83 (s, 1H), 7.32-7.28 (m,
2H), 7.23-7.20 (m, 1H), 4.38 (q, J = 7.1 Hz, 2H), 2,43 (s, 3H), 1.41 (t, J = 7.1 Hz, 3H); 13C NMR
δ 168.0, 164.6, 133.4, 129.9, 124.1, 122.9, 122.8, 122.0, 108.4, 105.3, 60.2, 18.1, 14.7; IR
(ATR) 3130, 2967, 1809, 1691, 1525, 1206, 1164 cm-1; HRMS (ESI) calculated for C13H14NO4
(M+H+) 248.0917; found, 248.09294.

Ethyl 1-tosyloxyindole-3-carboxylate (18). Treatment of 10 (91 mg, 0.39
mmol) in PhMe (5 mL) with sodium tert-pentoxide (40% solution in PhMe, 270 μL, 0.90
mmol) followed by p-toulenesulfonyl chloride (223 mg, 1.17 mmol) as described for 17
(ambient temperature, 3 h) gave after chromatography (hexane/EtOAc 7:3) 18 (62 mg, 0.17
mmol, 44%) as an oil which solidified upon standing to an orange solid. mp = 87-90 °C; 1H
NMR δ 8.11 (d, J = 7.9 Hz, 1H), 7.75 (d, J = 8.4 Hz, 2H), 7.67 (s, 1H), 7.32 (d, J = 8.0 Hz, 2H),
7.21 (t, J = 7.6 Hz, 1H), 7.12 (t, J = 7.7 Hz, 1H), 6.94 (d, J = 8.3 Hz, 1H), 4.36 (q, J = 7.1 Hz, 2H),
2.45 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H); 13C NMR δ 164.2, 147.8, 134.1, 130.7, 130.6, 129.7, 129.6,
124.3, 123.2, 122.5, 121.7, 109.3, 106.5, 60.4, 22.0, 14.6; IR (ATR) 2926, 1707, 1526, 1389,
1192, 1075 cm -1; HRMS (ESI) calculated for C18H18NO5S (M+H+) 360.0900; found, 360.0913.

Ethyl 1-hydroxyindole-3-carboxylate (19).10c Compound 10 (120 mg, 0.51
mmol) was added to a round-bottomed flask, and the system was purged with N2. Anhydrous
PhMe (6 mL) was added via syringe, and the solution and cooled to 0 °C. Sodium tertpentoxide (40% solution in PhMe, 350 μL, 1.17 mmol) was added dropwise, and the solution
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immediately turned purple. The mixture was allowed to warm to ambient temperature and
stirred for 3 h. The resultant mixture was quenched by addition of saturated aqueous
ammonium chloride and extracted with EtOAc (3 x 10 mL). The combined organic phases
were dried (MgSO4) and the solvent was removed under reduced pressure. The resulting
residue was purified by chromatography (hexane/EtOAc 1:1) to afford 19 (44 mg, 0.22
mmol, 42%) as an orange oil. 1H NMR δ 9.47 (s, 1H), 7.93 (d, J = 7.9 Hz, 1H), 7.64 (s, 1H), 7.46
(d, J = 7.2 Hz, 1H), 7.24 (t, J = 7.5 Hz, 1H), 7.19 (d, J = 7.2 Hz, 1H), 4.24 (q, J = 7.0 Hz, 2H), 1.32
(t, J = 7.1, 3H); 13C NMR δ 167.0, 134.0, 130.8, 123.4, 122.6, 122.5, 121.2, 109.4, 102.0.

Ethyl 2-iodo-2-pentenoate (20). N-iodosuccinimide (NIS, 1.18 g, 5.24
mmol) and NaH (60% dispersion in mineral oil, 590 mg, 14.7 mmol) were suspended in
tetrahydrofuran (THF, 15 mL). Triethylphosphonoacetate (830 μL, 4.19 mmol) was added
dropwise, and solution stirred at ambient temperature for 1 h. Propionaldehyde (300 μL,
4.19 mmol) was added dropwise via syringe, and the solution stirred at ambient temperature
for an additional 1 h. The reaction was quenched by slow addition of saturated aqueous
NH4Cl and extracted with ethyl acetate (3 x 15 mL). The combined organics were washed
sequentially with saturated aqueous NaHSO3 (15 mL) and H2O (15 mL), dried over MgSO4,
and the solvent was removed under reduced pressure. The resulting residue was purified by
chromatography over a short plug of silica (hexane/EtOAc 1:1) to afford 20 (1.02 g, 4.03
mmol, 96%) as a pale yellow oil, mixture of stereoisomers (major:minor = 2.6:1 by 1H NMR).
Analytical data from the 2.6:1 mixture of stereoisomers: 1H NMR (400 MHz, chloroform-d,
major isomer) δ 7.19 (t, J = 7.0 Hz, 1H), 4.26 (q, J = 7.1 Hz, 2H), 2.32 (m, 2H), 1.33 (t, J = 7.2
Hz, 3H), 1.11 (t, J = 7.3 Hz, 3H); 1H NMR (400 MHz, chloroform-d, minor isomer, partial data)
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δ 6.89 (t, J = 7.6 Hz, 1H), 4.19 (m, 2H), 2.47 (m, 2H); 13C NMR (101 MHz, chloroform-d, major
isomer) δ 162.9, 154.3, 94.6, 62.5, 30.5, 14.4, 11.8; 13C NMR (101 MHz, chloroform-d, minor
isomer) δ 163.8, 157.3, 84.2, 62.1, 29.6, 13.1, 12.1.

Ethyl 2-iodo-2-hexenoate (21). n-Butyraldehyde (500 μL, 5.57 mmol)
was reacted with triethylphosphonoacetate (1.10 mL, 5.57 mmol), NIS (1.57 g, 6.96 mmol),
and NaH (60% dispersion in mineral oil, 780 mg, 19.5 mmol) in THF (20 mL) as described
for 20. After purification over a short plug of silica gel (hexanes:EtOAc 1:1), 21 (1.24 g, 4.64
mmol, 83%) was obtained as a pale yellow oil, mixture of stereoisomers (major:minor = 2.1:1
by 1H NMR). Analytical data from the 2.1:1 mixture of stereoisomers: 1H NMR (400 MHz,
chloroform-d, major isomer) δ 7.20 (t, J = 7.0 Hz, 1H), 4.27 (q, J = 7.2 Hz, 2H), 2.29 (q, J = 7.3
Hz, 2H), 1.59-1.52 (m, 2H), 1.33 (t, J = 7.2 Hz, 3H), 0.99 (t, J = 7.4 Hz, 3H); 1H NMR (400 MHz,
chloroform-d, minor isomer, partial data) δ 6.89 (t, J = 7.8 Hz, 1H), 4.22-4.15 (m, 2H), 2.43 (q,
J = 7.6 Hz, 2H), 1.47 (m, 2H); 13C NMR (101 MHz, chloroform-d, major isomer) δ 171.0, 152.9,
95.2, 60.2, 38.8, 29.6, 20.8, 14.1; 13C NMR (101 MHz, chloroform-d, minor isomer) δ 166.2,
155.7, 84.5, 60.0, 35.2, 29.3, 20.9, 13.7.

Ethyl 2-iodo-2-octenoate (22). Hexanal (500 μL, 4.08 mmol) was
reacted with triethylphosphonoacetate (810 μL, 4.08 mmol), NIS (1.15 g, 5.10 mmol), and
NaH (60% dispersion in mineral oil, 570 mg, 14.3 mmol) in THF (15 mL) as described for 20.
After purification over a short plug of silica gel (hexanes:EtOAc 1:1), 22 (1.12 g, 3.77 mmol,
92%) was obtained as a pale yellow oil, mixture of stereoisomers (major:minor = 3.6:1 by 1H
NMR). Analytical data from the 3.6:1 mixture of stereoisomers: 1H NMR (400 MHz,
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chloroform-d, major isomer) δ 7.20 (t, J = 7.0 Hz, 1H), 4.27 (q, J = 7.2 Hz, 2H), 2.36-2.27 (m,
2H), 1.35-1.25 (m, 9H), 0.92-0.87 (m, 3H); 1H NMR (400 MHz, chloroform-d, minor isomer,
partial data) δ 6.90 (t, J = 7.7 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 2.45 (q, J = 7.6 Hz, 2H); 13C NMR
(101 MHz, chloroform-d, major isomer) δ 162.8, 153.2, 95.1, 62.5, 36.9, 31.3, 29.6, 27.1, 22.4,
13.9; 13C NMR (101 MHz, chloroform-d, minor isomer, partial data) δ 163.8, 149.4, 84.4, 62.0,
31.2, 29.3, 27.0, 22.3, 14.1; IR (ATR) 2955, 2925, 1717, 1464, 1367, 1242, 1175, 1038 cm-1;
HRMS (ESI) calculated for C10H18IO2 (M+H+) 297.03; found, 297.0346.

Ethyl 2-iodo-2-nonenoate (23). Heptanal (500 μL, 3.55 mmol)
was reacted with triethylphosphonoacetate (700 μL, 3.55 mmol), NIS (1.00 g, 4.44 mmol),
and NaH (60% dispersion in mineral oil, 500 mg, 12.4 mmol) in THF (15 mL) as described
for 20. After purification over a short plug of silica gel (hexanes:EtOAc 1:1), 23 (670 mg, 2.16
mmol, 61%) was obtained as a pale yellow oil, mixture of stereoisomers (major:minor = 6.3:1
by 1H NMR). Analytical data from the 6.3:1 mixture of stereoisomers: 1H NMR (400 MHz,
chloroform-d, major isomer) δ 7.20 (t, J = 7.0 Hz, 1H), 4.27 (q, J = 7.2 Hz, 2H), 2.31 (q, J = 7.2
Hz, 2H), 1.35-1.31 (m, 11H), 0.90-0.88 (m, 3H); 1H NMR (400 MHz, chloroform-d, minor
isomer, partial data) δ 6.90 (t, J = 7.7 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 2.45 (q, J = 7.6 Hz, 2H);
13C

NMR (101 MHz, chloroform-d, major isomer) δ 163.0, 153.3, 95.1, 62.6, 37.1, 31.6, 29.7,

29.0, 27.4, 22.5, 14.1; 13C NMR (101 MHz, chloroform-d, minor isomer, partial data) δ 156.2,
93.4, 62.1, 28.8, 22.7, 14.2.

Ethyl
Cyclohexanecarboxaldehyde

(500

3-cyclohexyl-2-iodopropenoate
μL,

4.13

mmol)

was

reacted

(24).
with
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triethylphosphonoacetate (820 μL, 4.13 mmol), NIS (1.16 g, 5.16 mmol), and NaH (60%
dispersion in mineral oil, 580 mg, 14.5 mmol) in THF (15 mL) as described for 20. After
purification over a short plug of silica gel (hexanes:EtOAc 1:1), 24 (705 mg, 2.29 mmol, 55%)
was obtained as a pale yellow oil, mixture of stereoisomers (major:minor = 4.5:1 by 1H NMR).
Analytical data from the 4.5:1 mixture of stereoisomers: 1H NMR (400 MHz, chloroform-d,
major isomer) δ 6.98 (d, J = 9.0 Hz, 1H), 4.26 (q, J = 7.1 Hz, 2H), 2.49-2.37 (m, 1H), 1.77-1.73
(m, 5H), 1.36-1.30 (m, 8H); 1H NMR (400 MHz, chloroform-d, minor isomer, partial data) δ
6.71 (d, J = 10.0 Hz, 1H), 2.91-2.78 (m, 1H); 13C NMR (101 MHz, chloroform-d, major isomer)
δ 163.1, 157.1, 92.7, 62.6, 45.9, 32.1, 30.5, 25.3, 14.2; 13C NMR (101 MHz, chloroform-d, minor
isomer, partial data) δ 160.5, 62.1, 31.9, 29.7, 25.7, 14.1.

Ethyl 2-iodo-4-phenylpentenoate (25). 2-Phenylpropionaldehyde
(500 μL, 3.74 mmol) was reacted with triethylphosphonoacetate (740 μL, 3.74 mmol), NIS
(1.05 g, 4.68 mmol), and NaH (60% dispersion in mineral oil, 520 mg, 13.1 mmol) in THF (15
mL) as described for 20. After purification over a short plug of silica gel (hexanes:EtOAc 1:1),
25 (348 mg, 1.06 mmol, 28%) was obtained as a yellow oil, mixture of stereoisomers
(major:minor = 2.1:1 by 1H NMR).Analytical data from the 4.8:1 mixture of stereoisomers:
1H

NMR (400 MHz, chloroform-d, major isomer) δ 7.33-7.30 (m, 3H), 7.24-7.18 (m, 2H), 7.11

(dd, J = 15.7, 6.7 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 3.62 (m, 1H), 1.44 (t, J = 7.0 Hz, 3H), 1.28 (d,
J = 7.1 Hz, 3H); 1H NMR (400 MHz, chloroform-d, minor isomer, partial data) δ 6.91 (d, J =
10.4 Hz, 1H), 3.76-3.71 (m, 1H); 13C NMR (101 MHz, chloroform-d, major isomer) δ 201.1,
166.8, 152.6, 143.3, 129.1, 128.7, 127.3, 126.7, 120.1, 60.3, 42.0, 20.2, 14.2; 13C NMR (101
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MHz, chloroform-d, minor isomer) δ 202.1, 163.0, 155.8, 142.4, 128.8, 127.2, 127.0, 62.8,
46.9, 19.5, 14.6; IR (ATR) 3027, 2976, 1715, 1493, 1452, 1367, 1264, 1173, 1028, 759 cm-1;
HRMS (ESI) calculated for C10H18IO2 (M+H+) 337.07; found, 337.1796.

Methyl 2-(2-nitrophenyl)-2-hexenoate (27).

Under an nitrogen

atmosphere, butyltriphenylphosphonium bromide (350 mg, 0.87 mmol) was dissolved in
THF (3 mL) and the solution was cooled to 0 °C. BuLi (2.5 M, 350 μL, 0.87 mmol) was added
drop wise via syringe and the resultant orange solution was stirred at 0 °C for 1 h. Compound
26 (150 mg, 0.72 mmol) dissolved in THF (2 mL) was added via syringe, and solution was
warmed to ambient temperature and stirred for 17 h. The reaction mixture was quenched
by addition of H2O and extracted with EtOAc (3 x 10 mL). The combined organic phases were
dried (MgSO4) and solvent was removed under reduced pressure. The resultant residue was
purified by chromatography (hexane/EtOAc 9:1) to afford 27 (43 mg, 0.17 mmol, 24%) as a
pale yellow oil as a mixture of stereoisomers (major/minor = 11.6:1 by 1H NMR). Analytical
data from the 11.6:1 mixture of stereoisomers: 1H NMR (major isomer) δ 8.14 (dd, J = 8.2,
1.3 Hz, 1H), 7.64 (td, J = 7.5, 1.3 Hz, 1H), 7.55-7.48 (m, 1H), 7.25 (d, J = 7.8 Hz, 1H), 7.12 (t, J
= 7.8 Hz, 1H), 3.70 (s, 3H), 2.04-1.89 (m, 2H), 1.45 (m, 2H), 0.86 (t, J = 7.4 Hz, 3H); 1H NMR
(minor isomer, partial data) δ 6.27 (t, J = 7.6 Hz, 1H), 2.82-2.72 (m, 2H);

13C

NMR (major

isomer) δ 166.2, 148.7, 145.0, 133.4, 132.7, 131.4, 129.0, 124.9, 52.3, 31.8, 22.0, 13.9.
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Methyl 2-(6-methoxy-2-nitrophenyl)-2-butenoate (29).

Under an

nitrogen atmosphere, methyl 2-(tributyltin)-2-butenoate26 (232 mg, 0.59 mmol) in PhMe (2
mL) was added via syringe to a solution of 2-bromo-1-methoxy-3-nitrobenzene (125 mg,
0.54 mmol), Pd(PPh3)4 (62 mg, 0.054 mmol) in PhMe (3 mL). The solution was heated to
reflux for 16 h, then cooled to ambient temperature, quenched with H2O, and extracted with
EtOAc (3 x 10 mL). The combined organic phases were washed with brine (3 x 10 mL), dried
(MgSO4), and the solvent was removed under reduced pressure. The resulting residue was
purified by chromatography (hexane/EtOAc 9:1 then 7:3) to afford 29 (35 mg, 0.14 mmol,
26%) as an orange oil as a mixture of stereoisomers (major/minor = 2.3:1 by 1H NMR).
Analytical data from the 2.3:1 mixture of stereoisomers: 1H NMR (major isomer) δ 7.63 (d, J
= 8.2 Hz, 1H), 7.46 (t, J = 8.4 Hz, 1H), 7.20 (dd, J = 14.2 7.6 Hz, 2H), 3.84 (s, 3H), 3.71 (s, 3H),
1.58 (d, J = 7.2 Hz, 3H); 1H NMR (minor isomer, partial data) δ 7.39 (t, J = 8.2 Hz, 1H), 7.11 (d,
J = 8.0 Hz, 1H), 6.15 (q, J = 7.3 Hz, 1H), 3.83 (s, 3H), 2.23 (d, J = 7.3 Hz, 3H); 13C NMR (major
isomer) δ 166.3, 157.8, 150.0, 141.5, 129.6, 126.8, 119.9, 116.3, 115.4, 56.6, 52.2, 15.6; 13C
NMR (minor isomer) δ 166.1, 158.2, 150.2, 143.6, 129.0, 125.6, 123.9, 115.9, 115.0, 57.2,
51.8, 16.3; IR (ATR) 2951, 1718, 1527, 1355, 1266, 1200, 1053; HRMS (ESI) calculated for
C12H14NO5 (M+H+) 252.0866; found, 252.0878.

Methyl 2-(5-methoxy-2-nitrophenyl)-2-butenoate (30). Treatment
of 1-bromo-5-methoxy-2-nitrobenzene (270 mg, 1.17 mmol) in PhMe (6 mL) with Pd(PPh3)4
(140 mg, 0.12 mmol) and methyl 2-(tributyltin)-2-butenoate (500 mg, 1.29 mmol), as
60

described for 29 (reflux, 16 h), gave after chromatography (hexane/EtOAc 9:1 then 7:3) 30
(117 mg, 0.47 mmol, 40%) as an orange oil as a mixture of stereoisomers (major/minor =
15.9:1 by 1H NMR). Analytical data from the 15.9:1 mixture of stereoisomers: 1H NMR (major
isomer) δ 8.22 (d, J = 9.1 Hz, 1H), 7.17 (q, J = 7.2 Hz, 1H), 6.97 (dd, J = 9.2, 2.8 Hz, 1H), 6.70
(d, J = 2.8 Hz, 1H), 3.90 (s, 3H), 3.69 (s, 3H), 1.72 (d, J = 7.2 Hz, 3H); 1H NMR (minor isomer,
partial data) δ 8.14 (d, J = 9.1 Hz, 1H), 6.92 (dd, J = 9.1, 2.8 Hz, 1H), 6.78 (d, J = 2.8 Hz, 1H),
6.35 (q, J = 7.3 Hz, 1H), 3.65 (s, 3H), 2.30-2.27 (m, 3H);

13C

NMR (major isomer) δ 166.0,

163.3, 141.5, 139.0, 133.8, 132.9, 127.6, 117.8, 113.4, 56.1, 52.2, 15.5;

13C

NMR (minor

isomer, partial data) δ 165.5, 163.6, 142.1, 138.2, 135.3, 132.8, 127.3, 117.9, 113.2, 51.6, 16.1;
IR (ATR) 2950, 1713, 1576, 1509, 1336, 1233, 1041 cm-1; HRMS (ESI) calculated for
C12H14NO5 (M+H+) 252.0866; found, 252.0879.

Methyl 2-(4-methoxy-2-nitrophenyl)-2-butenoate (31). Treatment
of 1-bromo-4-methoxy-2-nitrobenzene (126 mg, 0.55 mmol) in PhMe (5 mL) with Pd(PPh3)4
(64 mg, 0.06 mmol), and methyl 2-(tributyltin)-2-butenoate (234 mg, 0.60 mmol), as
described for 29 (reflux, 16 h), gave after chromatography (hexane/EtOAc 9:1 then 7:3) 31
(59 mg, 0.24 mmol, 43%) as an orange oil, mixture of stereoisomers (major/minor = 11.7:1
by 1H NMR). Analytical data from the 11.7:1 mixture of stereoisomers: 1H NMR (major
isomer) δ 7.66 (s, 1H), 7.21-7.12 (m, 3H), 3.91 (s, 3H), 3.69 (s, 3H), 1.71 (d, J = 7.1 Hz, 3H); 1H
NMR (minor isomer, partial data) δ 7.58 (s, 1H), 6.38-6.29 (m, 1H), 3.89 (s, 3H), 3.65 (s, 3H),
2.27 (d, J = 7.8 Hz, 3H); 13C NMR (major isomer) δ 166.4, 159.7, 149.1, 139.8, 133.5, 132.0,
123.0, 120.0, 109.5, 56.1, 52.3, 15.7;

13C

NMR (minor isomer) δ 165.9, 159.5, 148.3, 142.4,
61

135.6, 131.7, 121.5, 120.2, 109.4, 56.2, 51.7, 16.3; IR (ATR) 2951, 1720, 1530, 1351, 1235,
1032 cm-1; HRMS (ESI) calculated for C12H14NO5 (M+H+) 252.0866; found, 252.0878.

Methyl 2-(3-methoxy-2-nitrophenyl)-2-butenoate (32). Treatment of 1bromo-3-methoxy-2-nitrobenzene (148 mg, 0.64 mmol) in PhMe (5 mL) with Pd(PPh3)4 (74
mg, 0.06 mmol), and methyl 2-(tributyltin)-2-butenoate (500 mg, 1.29 mmol), as described
for 29 (reflux, 48 h), gave after chromatography (hexane/EtOAc 7:3 then 1:1) 32 (76 mg,
0.30 mmol, 47%) as an orange oil, mixture of stereoisomers (major:minor = 6.0/1 by 1H
NMR). Analytical data from the 6.0:1 mixture of stereoisomers: 1H NMR (major isomer) δ
7.45 (t, J = 8.1 Hz, 1H), 7.26 (q, J = 7.2 Hz, 1H), 7.06 (d, J = 8.5 Hz, 1H), 6.79 (d, J = 7.7 Hz, 1H),
3.93 (s, 3H), 3.71 (s, 3H), 1.69 (d, J = 7.2 Hz); 1H NMR (minor isomer) δ 7.40 (t, J = 8.1 Hz, 1H),
7.01 (d, J = 8.5 Hz, 1H), 6.87 (d, J = 7.8 Hz, 1H), 6.38 (q, J = 7.3 Hz, 1H), 3.91 (s, 3H), 3.70 (s,
3H), 2.19 (d, J = 7.3 Hz, 3H);

13C

NMR (major isomer) δ 165.9, 151.2, 144.1, 133.8, 131.3,

130.0, 129.6, 122.7, 112.3, 56.6, 52.4, 15.8;

13C

NMR (minor isomer, partial data) δ 151.1,

145.1, 131.1, 129.1, 122.8, 112.0, 56.6, 51.9, 16.4; IR (ATR) 2951, 1718, 1578, 1530, 1434,
1369, 1263, 1224, 1038 cm-1; HRMS (ESI) calculated for C12H14NO5 (M+H+) 252.0866; found,
252.0878.

Methyl

2-(5-carbomethoxy-2-nitrophenyl)-2-butenoate

(33).

Under a nitrogen atmosphere, methyl 2-(tributyltin)-2-butenoate (500 mg, 1.29 mmol) in
PhMe (4 mL) was added via syringe to a solution of 3-bromo-4-nitrobenzoic acid methyl
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ester (303 mg, 1.17 mmol), PdCl2(PPh3)2 (16 mg, 0.02 mmol), PPh3 (12 mg, 0.05 mmol) in
PhMe (8 mL). The solution was heated to reflux for 24 h, then cooled to ambient temperature,
quenched with H2O, and extracted with EtOAc (3 x 10 mL). The combined organics were
washed with brine (3 x 10 mL), dried (MgSO4), and the solvent was removed under reduced
pressure. The resulting residue was purified by chromatography (hexane/EtOAc 9:1 then
7:3 gradient) to afford 33 (180 mg, 0.65 mmol, 55%) as a pale orange oil, mixture of
stereoisomers (major/minor = 5.5:1 by 1H NMR). Analytical data from the 5.5:1 mixture of
stereoisomers: 1H NMR (major isomer) δ 8.17 (s, 2H), 7.94 (s, 1H), 7.28 (q, J = 7.3 Hz, 1H),
3.97 (s, 3H), 3.70 (s, 3H), 1.74 (d, J = 7.3 Hz, 3H); 1H NMR (minor isomer, partial data) δ 8.01
(s, 1H), 6.48 (q, J = 7.6 Hz, 1H), 3.66 (s, 3H), 2.32 (d, J = 7.3 Hz, 3H); 13C NMR (major isomer)
δ 165.7, 165.2, 151.2, 144.4, 141.1, 134.3, 134.1, 131.3, 130.2, 125.1, 53.1, 52.4, 15.8; 13C NMR
(minor isomer, partial data) δ 141.9, 134.5, 133.9, 131.2, 129.9, 124.7, 52.2, 51.8, 16.5; IR
(ATR) 2954, 1726, 1529, 1437, 1347, 1283, 1250, 1116 cm-1; HRMS (ESI) calculated for
C13H14NO6 (M+H+) 280.0972; found, 280.0828.

Methyl

2-(4-carbomethoxy-2-nitrophenyl)-2-butenoate

(34).

Treatment of 4-bromo-3-nitrobenzoic acid methyl ester (97 mg, 0.38 mmol) in PhMe (5 mL)
with Pd(PPh3)4 (43 mg, 0.04 mmol), and methyl 2-(tributyltin)-2-butenoate (160 mg, 0.41
mmol) as described for 29 (reflux, 24 h) gave after chromatography (hexane/EtOAc 7:3 to
1:1 gradient) 34 (65 mg, 0.23 mmol, 62%) as a yellow oil, mixture of stereoisomers
(major/minor = 10.9:1

by

1H

NMR). Analytical data from the 10.9:1 mixture of

stereoisomers: 1H NMR (DMSO-d6) (major isomer) δ 8.58 (s, 1H), 8.30 (d, J = 8.0 Hz, 1H), 7.61
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(d, J = 7.9 Hz, 1H), 7.21 (q, J = 7.2 Hz, 1H), 3.94 (s, 3H), 3.62 (s, 3H), 1.71 (d, J = 7.2 Hz, 3H); 1H
NMR (DMSO-d6) (minor isomer) δ 8.49 (s, 1H), 8.27 (d, J = 7.4 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H),
6.66 (q, J = 7.4 Hz, 1H), 3.56 (s, 3H), 2.24 (d, J = 7.3 Hz, 3H);

13C

NMR (DMSO-d6) (major

isomer) δ 164.8, 164.3, 148.2, 141.4, 134.3, 133.8, 133.7, 130.7, 130.5, 125.1, 52.9, 52.1, 15.5;
13C

NMR (DMSO-d6) (minor isomer, partial data) δ 149.6, 132.2, 123.9; IR (ATR) 2954, 1726,

1534, 1436, 1350, 1280, 1198, 1114 cm-1; HRMS (ESI) calculated for C13H14NO6 (M+H+)
280.0972; found, 280.0829.

Methyl 1-hydroxy-5-methoxyindole-3-carboxylate (35). Treatment
of 30 (89 mg, 0.36 mmol) in PhMe (5 mL) with sodium tert-pentoxide (40% solution in PhMe,
250 μL, 0.83 mmol), as described for 19 (ambient temperature, 3 h), gave after
chromatography (hexane/EtOAc 7:3) 35 (28 mg, 0.13 mmol, 36%) as an orange oil. 1H NMR
(DMSO-d6) δ 10.90 (s, br, 1H), 6.95 (s, 1H), 6.34 (d, J = 2.3 Hz, 1H), 6.26 (d, J = 8.9 Hz, 1H),
5.78 (dd, J = 8.9, 2.4 Hz, 1H), 2.65 (s, 3H), 2.65 (s, 3H); 13C NMR (DMSO-d6) δ 164.6, 155.6,
130.4, 128.8, 123.3, 113.2, 110.6, 102.0, 100.1, 55.5, 50.9; IR (ATR) 3213, 2951, 1657,
1435,1367, 1264, 1209, 1088, 1012 cm-1; HRMS (ESI) calculated for C11H12NO4 (M+H+)
222.0761; found, 222.0771.

Methyl 1,5-dimethoxyindole-3-carboxylate (36). Treatment of 30
(28 mg, 0.11 mmol) in PhMe (5 mL) with sodium tert-pentoxide (40% solution in PhMe, 28
μL, 0.25 mmol) followed by dimethyl sulfate (32 μL, 0.34 mmol), as described for 12
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(ambient temperature, 3 h) gave after chromatography (hexane/EtOAc 7:3) 36 (16 mg, 0.07
mmol, 60%) as an orange oil. 1H NMR δ 7.89 (s, 1H), 7.65 (d, J = 2.4 Hz, 1H), 7.35 (d, J = 8.9
Hz, 1H), 6.96 (dd, J = 8.9, 2.4 Hz, 1H), 4.13 (s, 3H), 3.90 (s, 3H), 3.89 (s, 3H); 13C NMR δ 165.3,
156.5, 128.3, 127.2, 123.9, 114.4, 109.7, 103.0, 102.8, 66.9, 56.0, 51.2; IR (ATR) 2942, 1699,
1518, 1456, 1369, 1262, 1201, 1086, 1016; HRMS (ESI) calculated for C12H14NO4 (M+H+)
236.0917; found, 236.0929.

Methyl

1-hydroxy-6-methoxyindole-3-carboxylate

(37).

Treatment of 31 (44 mg, 0.18 mmol) in PhMe (3 mL) with sodium tert-pentoxide (40%
solution in PhMe, 121 μL, 0.41 mmol), as described for 19 (ambient temperature, 3 h), gave
after chromatography (hexane/EtOAc 1:1) 37 (16 mg, 0.07 mmol, 42%) as an orange solid.
mp = 137-140 °C; 1H NMR δ 9.13 (s, br, 1H), 7.81 (d, J = 8.7 Hz, 1H), 7.59 (s, 1H), 6.94-6.76
(m, 2H), 3.81 (s, 3H), 3.80 (s, 3H); 13C NMR (CDCl3, DMSO-d6) δ 163.7, 155.6, 133.3, 128.0,
120.6, 115.5, 111.1, 100.2, 90.5, 54.2, 49.6; IR (ATR) 3118, 1651, 1503, 1435, 1233, 1082 cm1;

HRMS (ESI) calculated for C11H12NO4 (M+H+) 222.0761; found, 222.0772.

Methyl 1,6-dimethoxyindole-3-carboxylate (38). Treatment of 31
(56 mg, 0.22 mmol) in PhMe (3 mL) with sodium tert-pentoxide (40% solution in PhMe, 154
μL, 0.51 mmol) followed by dimethyl sulfate (63 μL, 0.66 mmol), as described for 12
(ambient temperature, 3 h), gave after chromatography (hexane/EtOAc 7:3) 38 as an
inseparable mixture with an unknown impurity. Alternative synthesis of 38. To a solution
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of 37 (16 mg, 0.07 mmol) in acetone (3 mL) was added K2CO3 (19 mg, 0.14 mmol). The
resulting suspension was stirred at ambient temperature for 10 min., then MeI (6 μL, 0.10
mmol) was added and solution stirred for an additional 4 h at ambient temperature. Water
was added to the reaction mixture followed by extraction with EtOAc (3 x 10mL). The
combined organic phases were dried (MgSO4) and solvent was removed under reduced
pressure. The resulting residue was purified by chromatography (hexane/EtOAc 7:3) to
afford pure 38 (16 mg, 0.07 mmol, 94%) as a pale yellow oil that solidified upon standing.
mp = 69-70 °C; 1H NMR δ 8.02 (dd, J = 8.7, 0.6 Hz, 1H), 7.86 (s, 1H), 6.94-6.89 (m, 2H), 4.13
(s, 3H), 3.90 (s, 3H), 3.89 (s, 3H); 13C NMR δ 165.2, 157.6, 133.0, 127.4, 122.8, 117.0, 112.7,
103.7, 91.7, 66.6, 55.8, 51.3; IR (ATR) 2945, 1699, 1521, 1440, 1230, 1078, 1016; HRMS (ESI)
calculated for C12H14NO4 (M+H+) 236.0917; found, 236.0928.

Methyl 5-carbomethoxy-1-hydroxyindole-3-carboxylate (39).
Treatment of 33 (115 mg, 0.41 mmol) in PhMe (5 mL) with sodium tert-pentoxide (40%
solution in PhMe, 285 μL, 0.94 mmol), as described for 19 (ambient temperature, 3 h), gave
after chromatography (hexane/EtOAc 1:1) 39 (30 mg, 0.12 mmol, 29%) as a pale orange
solid. mp = 148-150 °C; 1H NMR δ 11.34 (s br, 1H), 8.86 (s, 1H), 8.01-7.95 (m, 2H), 7.54 (d, J
= 8.7 Hz, 1H), 3.95 (s, 3H), 3.93 (s, 3H);

13C

NMR (CDCl3, DMSO-d6) δ 167.4, 164.4, 135.6,

131.4, 123.7, 123.6, 123.3, 121.5, 108.6, 102.8, 51.5, 50.7; IR (ATR) 3390, 2953, 1704, 1281,
992, 763 cm-1; HRMS (ESI) calculated for C12H12NO5 (M+H+) 250.0710; found, 250.1198.
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Methyl 5-carbomethoxy-1-methoxyindole-3-carboxylate (40).
Treatment of 33 (65 mg, 0.23 mmol) in PhMe (5 mL) with sodium tert-pentoxide (40%
solution in PhMe, 160 μL, 0.53 mmol) followed by dimethyl sulfate (66 μL, 0.69 mmol) as
described for 12 (ambient temperature, 3 h) gave after chromatography (hexane/EtOAc 7:3)
40 as an inseparable mixture with an unknown impurity. Alternative synthesis of 40. To a
solution of 39 (11 mg, 0.04 mmol) in acetone (3 mL) was added K2CO3 (12 mg, 0.09 mmol).
The resulting suspension was stirred at ambient temperature for 10 min., then MeI (4 μL,
0.07 mmol) was added and the solution stirred for an additional 4 h at ambient temperature.
The resultant mixture was quenched with H2O and extracted with EtOAc (3 x 10 mL). The
combined organic phases were dried (MgSO4) and solvent was removed under reduced
pressure. The residue was purified by chromatography (hexane/EtOAc 7:3) to afford pure
40 (11 mg, 0.04 mmol, 93%) as a pale yellow oil that solidified upon standing. mp = 128-130
°C; 1H NMR δ 8.89 (dd, J = 1.5, 0.6 Hz, 1H), 8.05-8.02 (m, 2H), 7.50 (dd, J = 8.7, 0.6 Hz, 1H),
4.17 (s, 3H), 3.96 (s, 3H), 3.95 (s, 3H);

13C

NMR δ 167.8, 164.7, 134.4, 130.0, 125.0, 124.8,

124.7, 122.2, 108.6, 105.1, 67.1, 52.3, 51.6; IR (ATR) 2949, 1708, 1434, 1367, 1277, 1202,
1081, 1023 cm-1; HRMS (ESI) calculated for C13H14NO5 (M+H+) 264.0866; found, 264.0880.

Methyl 6-carbomethoxy-1-hydroxyindole-3-carboxylate (41).
Treatment of 34 (110 mg, 0.40 mmol) in PhMe (5 mL) with sodium tert-pentoxide (40%
solution in PhMe, 277 μL, 0.92 mmol) as described for 19 (ambient temperature, 3 h) gave
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after chromatography (hexane/EtOAc 1:1) 41 (24 mg, 0.10 mmol, 25%) as a pale orange
solid. mp = 156-157 °C; 1H NMR (DMSO-d6) δ 12.31 (s, br, 1H), 8.40 (s, 1H), 8.11-8.08 (m,
2H), 7.82 (d, J = 8.3 Hz, 1H), 3.88 (s, 3H), 3.82 (s, 3H); 13C NMR (DMSO-d6) δ 166.5, 163.8,
133.5, 132.9, 125.6, 123.9, 122.2, 120.6, 111.2, 101.3, 52.1, 51.0; IR (ATR) 3394, 1697, 1256,
1211, 1023, 993, 762 cm-1; HRMS (ESI) calculated for C12H12NO5 (M+H+) 250.0710; found,
250.1198.

Methyl 6-carbomethoxy-1-methoxyindole-3-carboxylate (42).
Treatment of 34 (41 mg, 0.15 mmol) in PhMe (3 mL) with sodium tert-pentoxide (40%
solution in PhMe, 101 μL, 0.35 mmol) followed by dimethyl sulfate (42 μL, 0.45 mmol) as
described for 12 (ambient temperature, 3 h) gave after chromatography (hexane/EtOAc 7:3)
a 14.3:1 inseparable mixture of 42/34 (11.7:1 by 1H NMR) (17 mg, 0.07 mmol, 44%,
calculated from spectrum) as an orange oil. 1H NMR δ 8.23-8.19 (m, 2H), 8.09 (s, 1H), 7.96
(dd, J = 8.4, 1.5 Hz, 1H), 4.20 (s, 3H), 3.97 (s, 3H), 3.93 (s, 3H); 13C NMR δ 167.5, 164.7, 131.7,
131.1, 126.3, 125.6, 123.5, 121.7, 11.2, 104.1, 67.4, 52.4, 51.5; IR (ATR) 2950, 1707, 1437,
1381, 1254, 1206, 1070, 776 cm-1; HRMS (ESI) calculated for C13H14NO5 (M+H+) 264.0866;
found, 264.0880.

6-Amino-7-bromo-2,3-dihydro-5-methylinden-1-one

(75).

2,3,5,6-

Tetrabromo-4-methyl-4-nitrocyclohexa-2,5-dienone 74 (2.13 g, 4.55 mmol) was added to a
stirred solution of 68 (733 mg, 4.55 mmol) in AcOH (5 mL). The resulting solution was
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stirred for 4 hours at ambient temperature and then poured into a 10% NaHCO3 (aq) solution
(15 mL). The suspension was extracted with CH2Cl2 (3 x 30 mL) and the combined organics
were washed with H2O (2 x 30 mL), dried (MgSO4), filtered, and concentrated in vacuo. The
resulting residue was purified by flash chromatography (hexanes:EtOAc 8:2) to afford 75
(640 mg, 2.66 mmol, 59%) as a brown solid. mp=177-179 °C; 1H NMR (600 MHz, CDCl3) δ
2.30 (s, 3H), 2.67-2.72 (m, 2H), 2.93-2.97 (m, 2H), 4.26 (br s, 2H), 7.11 (s, 1H); 13C NMR (151
MHz, CDCl3) δ 19.2, 23.8, 37.4, 103.6, 126.7, 131.2, 132.5, 142.4, 147.4, 204.2; IR (ATR) 871,
1318, 1469, 1621, 1688, 3352, 3378 cm-1; HRMS (ESI) calculated for C10H11BrNO (M+H+)
240.0024, found 240.0018.

N-(2,3-Dihydro-5-methyl-1-oxo-1H-inden-6-yl)acetamide (69). To a
stirring solution of 68 (4.62 g, 28.7 mmol) in 100 mL of CH2Cl2 was added NEt3 (3.19 g, 31.5
mmol) at ambient temperature and the solution was allowed to stir for 15 min. Acetyl
chloride (2.70 g, 34.4 mmol) was then added dropwise and the reaction mixture was stirred
for 22 h at ambient temperature. The crude mixture was washed with water (2 x 100 mL)
and brine (1 x 100 mL), dried (MgSO4), filtered, and concentrated in vacuo. The residue was
purified by flash chromatography (EtOAc) to give 69 (4.86 g, 23.9 mmol, 84%) as a tan solid.
mp = 221-223 °C; 1H NMR (600 MHz, CDCl3) δ 2.21 (s, 3H), 2.34 (s, 3H), 2.66-2.68 (m, 2H),
3.05-3.07 (m, 2H), 7.14 (br s, 1H), 7.31 (s, 1H), 7.95 (s, 1H); 13C NMR (151 MHz, CDCl3) δ 18.9,
24.0, 25.3, 36.6, 119.2, 128.4, 135.2, 136.0, 138.8, 152.4, 168.5, 206.0; IR (ATR) 864, 1527,
1656, 1691, 3310 cm-1; HRMS (ESI) calculated for C12H14NO2 (M+H+) 204.1019, found
204.1019.
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N-(2,3-Dihydro-5-methyl-7-nitro-1-oxo-1H-inden-6-yl)acetamide (70).
Fuming nitric acid (10 mL) was stirred at -20 °C for 5 min, then 25 drops of concentrated
H2SO4 was added and the resulting mixture was stirred at -20 °C for 20 min. This mixture
was added dropwise to 69 (1.0 g, 4.92 mmol), cooled to -20 °C, and stirred at the same
temperature for 1.5 h before quenching with 20 mL of H2O and then 20 mL of a saturated
NH4Cl solution (aq). The aqueous mixture was extracted with EtOAc (3 x 50 mL) and washed
with H2O (3 x 50 mL). The organic phase was dried (MgSO4), filtered, and concentrated in
vacuo. The resulting residue was purified by flash chromatography (EtOAc) to afford 70 (860
mg, 3.46 mmol, 70%) as a dark yellow solid. mp = 225-227 °C; 1H NMR δ 2.18 (s, 3H), 2.39
(s, 3H), 2.77-2.79 (m, 2H), 3.14-3.16 (m, 2H), 7.31 (br s, 1H), 7.53 (s, 1H); 13C NMR δ 19.5,
23.2, 25.3, 36.8, 126.1, 126.7, 130.7, 142.4, 146.3, 154.6, 168.9, 200.4; IR (ATR) 782, 1536,
1673, 1718, 3347 cm-1; HRMS (ESI) calculated for C12H13N2O4 (M+H+) 249.0870, found
249.0871.

6-Amino-2,3-dihydro-5-methyl-7-nitroinden-1-one (71). A solution of 70
(140 mg, 0.56 mmol) in EtOH (15 mL) was refluxed with 5 M HCl (aqueous, 10 mL) for 18 h.
The organic phase was removed in vacuo and the resulting aqueous solution was made
alkaline (pH 8-9) with a NaOH solution (aq). This solution was then extracted with CH2Cl2 (3
x 20 mL), dried (MgSO4), filtered, and concentrated in vacuo. The resulting residue was
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purified by flash chromatography (hexanes:EtOAc 1:1) to afford 71 (98 mg, 0.48 mmol, 84%)
as a bright yellow solid. mp = 229-231 °C; 1H NMR (600 MHz, CDCl3) δ 2.32 (s, 3H), 2.72-2.74
(m, 2H), 2.97-2.99 (m, 2H), 5.10 (br s, 2H), 7.31 (s, 1H); 13C NMR (151 MHz, CDCl3) δ 18.6,
24.6, 37.1, 129.0, 131.2, 133.6, 139.7, 145.7, 200.6 (1 resonance not found); IR (ATR) 887,
1313, 1518, 1634, 1689, 3362, 3460 cm-1; HRMS (ESI) calculated for C10H11N2O3 (M+H+)
207.0764, found 207.0764.

2,3-Dihydro-6-iodo-5-methyl-7-nitroinden-1-one

(72).

To

a

stirred

solution of 71 (21 mg, 0.10 mmol) in concentrated HCl (1 mL) and ice at 0 °C, a solution of
sodium nitrite (8 mg, 0.11 mmol) in H2O (1 mL) was added dropwise. The mixture was
stirred at 0 °C for 30 min before adding it dropwise to a stirred solution of KI (50 mg, 0.30
mmol) in H2O (1 mL) at ambient temperature. The mixture remained stirring for 16 hours at
ambient temperature and was then extracted with CH2Cl2 (3 x 20 mL). The combined organic
extracts were washed with 10% NaOH (aq.) (1 x 20 mL), 5% NaHCO3 (aq.) (1 x 20 mL), and
H2O (1 x 20 mL) before being dried (MgSO4), filtered, and concentrated in vacuo. The
resulting dark yellow residue was purified by flash chromatography (hexanes: EtOAc, 9:1
then 8:2) to afford 72 (20 mg, 0.063 mmol, 63%) as an off-white solid. mp = 173-175 °C; 1H
NMR δ 2.60 (s, 3H), 2.73-2.75 (m, 2H), 2.98-3.00 (m, 2H), 7.28 (s, 1H); 13C NMR δ 24.5, 31.1,
36.9, 107.4, 125.8, 131.8, 136.3, 150.5, 156.8, 201.9; IR (ATR) 871, 1149, 1432, 1694, 2923
cm-1; HRMS (ESI) calculated for C10H9INO3 (M+H+) 317.9627 (peak not found
experimentally).
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6-Bromo-2,3-dihydro-5-methylinden-1-one (76).
Method 1 (Table 5, entry 1): A solution of 68 (100 mg, 0.62 mmol) in HBr (48%, 500 μL), H2O
(1 mL), and 1,4-dioxane (500 μL) was heated to reflux for 20 min. The resulting solution was
cooled to ambient temperature, then placed in an ice bath. A solution of NaNO2 (40 mg, 0.62
mmol) in H2O (1 mL) was added dropwise, and the resulting orange solution stirred at 0 °C
for 20 min. This solution was added dropwise to a solution of CuBr (100 mg, 0.68 mmol) in
HBr (48%, 500 μL) and H2O (1 mL) at 0 °C, during which time the evolution of gas was
observed. The dark red-brown solution was warmed to ambient temperature and stirred for
16 h. The solution was quenched by slow addition of saturated NaHCO3 (aq) and extracted
with EtOAc (3 x 10 mL). The combined organics were washed with H 2O (10 mL), dried
(MgSO4), filtered, and concentrated in vacuo. The resulting residue was purified by flash
chromatography (hexanes:EtOAc 8:2) to afford 76 (104 mg, 0.46 mmol, 75%) as an orange
solid.
Method 2 (Table 5, entry 3): 67 (2.0 g, 13.7 mmol) was added to stirring conc. H2SO4 (15 mL)
at ambient temperature. N-bromosuccinimide (NBS, 3.05 g, 17.1 mmol) was added in
portions, and the resulting orange solution stirred at ambient temperature for 3 h. The
reaction was quenched by addition of ice chips and the solution was extracted with EtOAc (3
x 15 mL). The combined organics were washed with saturated NaHCO3 (aq, 15 mL) and brine
(15 mL), dried (MgSO4), filtered, and concentrated in vacuo. The resulting residue was
purified by flash chromatography (hexanes: EtOAc, 9:1 to 7:3 gradient) to afford 76 (973 mg,
4.33 mmol, 32%) as an orange solid, and 77 (1.26 g, 5.61 mmol, 41%) as a pale orange solid.
72

Analytical data for 76: mp = 114-116 oC; 1H NMR (600 MHz, CDCl3) δ 7.92 (s, 1H), 7.36 (s,
1H), 3.07-3.04 (m, 2H), 2.71-2.68 (m, 2H), 2.48 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 205.1,
154.0, 144.9, 136.7, 128.6, 127.4, 124.4, 36.5, 25.3, 23.9; IR (ATR) 1702, 1597, 1432, 1379,
1171, 884 cm-1; HRMS (ESI) calculated for C10H10BrO (M+H+) 224.9915, found 224.9918.

4-Bromo-2,3-dihydro-5-methylinden-1-one (77).
Method 1 (Table 5, entry 2): 67 (500 mg, 3.42 mmol) in CH2Cl2 (4 mL) was added dropwise
over 30 min to a suspension of AlCl3 (910 mg, 6.84 mmol) in CH2Cl2 (4 mL). To this solution
was added Br2 (190 μL, 3.76 mmol) in CH2Cl2 (4 mL) dropwise. The resulting dark redorange solution was heated to 50 C and stirred for 22 h. The solution was cooled to ambient
temperature and quenched by slow addition of H2O (5 mL). The organics were washed with
H2O (10 mL) and brine (10 mL), dried (MgSO4), filtered, and concentrated in vacuo. The
resulting residue was purified by flash chromatography (hexanes:EtOAc 9:1) to afford 77
(92 mg, 0.41 mmol, 12%) as a pale orange solid.
Method 2 (Table 5, entry 3): 67 (2.0 g, 13.7 mmol) was added to stirring conc. H2SO4 (15 mL)
at ambient temperature. N-bromosuccinimide (NBS, 3.05 g, 17.1 mmol) was added in
portions, and the resulting orange solution stirred at ambient temperature for 3 h. The
reaction was quenched by addition of ice chips and the solution was extracted with EtOAc (3
x 15 mL). The combined organics were washed with saturated NaHCO3 (aq, 15 mL) and brine
(15 mL), dried (MgSO4), filtered, and concentrated in vacuo. The resulting residue was
purified by flash chromatography (hexanes: EtOAc, 9:1 to 7:3 gradient) to afford 76 (973 mg,
4.33 mmol, 32%) as an orange solid, and 77 (1.26 g, 5.61 mmol, 41%) as a pale orange solid.
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Analytical data for 77: mp = 65-68 oC; 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 7.7 Hz, 1H),
7.27 (d, J = 9.7 Hz, 1H), 3.09-3.05 (m, 2H), 2.75-2.72 (m, 2H), 2.51 (s, 3H); 13C NMR (151 MHz,
CDCl3) δ 205.8, 155.4, 145.1, 136.8, 130.2, 124.1, 122.0, 36.4, 27.5, 23.1; IR (ATR) 1702, 1595,
1258, 1116, 1038, 808 cm-1; HRMS (ESI) calculated for C10H10BrO (M+H+) 224.9915, found
224.9917.

6-Bromo-2,3-dihydro-5-methyl-4-nitroinden-1-one (78). 76 (1.52 g,
6.77 mmol) was reacted with fuming HNO3 (15 mL) and conc. H2SO4 (40 drops) as described
for 70 (-20 °C, 90 min). After chromatography (hexanes:EtOAc 7:3 then EtOAc), 78 (317 mg,
1.18 mmol, 17%, off-white solid) and 79 (1.15 g, 4.30 mmol, 64%, orange solid) were
obtained. Analytical data for 78: mp = 145 °C (sublimation); 1H NMR (600 MHz, chloroformd) δ 8.11 (s, 1H), 3.20-3.16 (m, 2H), 2.80-2.76 (m, 2H), 2.56 (s, 3H);

13C

NMR (151 MHz,

chloroform-d) δ 202.6, 147.0, 145.8, 137.8, 137.3, 130.2, 126.2, 35.9, 23.9, 19.6; IR (ATR)
3069, 1712, 1527, 1356, 1241, 1199, 1161 cm-1; HRMS (ESI) calculated for C10H9BrNO3
(M+H+) 271.97, found 271.9748.

6-Bromo-2,3-dihydro-5-methyl-7-nitroinden-1-one (79). 76 (1.52 g, 6.77
mmol) was reacted with fuming HNO3 (15 mL) and conc. H2SO4 (40 drops) as described for
70 (-20 °C, 90 min). After chromatography (hexanes:EtOAc 7:3 then EtOAc), 78 (317 mg,
1.18 mmol, 17%, off-white solid) and 79 (1.15 g, 4.30 mmol, 64%, orange solid) were
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obtained. Analytical data for 79: mp = 137-138 °C; 1H NMR (600 MHz, chloroform-d) δ 7.51
(s, 1H), 3.14-3.11 (m, 2H), 2.80-2.78 (m, 2H), 2.57 (s, 3H); 13C NMR (151 MHz, chloroform-d)
δ 199.7, 154.7, 147.0, 145.4, 129.7, 126.3, 114.1, 36.3, 25.0, 23.9; IR (ATR) 2928, 1704, 1599,
1538, 1431, 1375, 1309, 1165, 887, 801 cm-1; HRMS (ESI) calculated for C10H9BrNO3 (M+H+)
271.97, found 271.9745.

6-(3-hydroxy-1-propenyl)-2,3-dihydro-5-methyl-7-nitroinden-1one (64). To an oven-dried flask equipped with a cold water condenser were added 79 (688
mg, 2.56 mmol), PdCl2(PPh3)2 (36 mg, 0.05 mmol), and PPh3 (27 mg, 0.10 mmol), and the
system was purged with N2. 1,4-dioxane (anhydrous, 15 mL) was added via syringe, and the
solution was stirred at ambient temperature. (E)-3-(tributylstannyl)-2-propen-1-ol (65,
1.15 g, 3.33 mmol) in 1,4-dioxane (anhydrous, 5 mL) was added via syringe and the solution
was heated to 110 °C for 120 h. The resulting reaction mixture was cooled to ambient
temperature and quenched with H2O (20 mL). Solution was extracted with EtOAc (3 x 30
mL). The combined organics were washed with brine (3 x 30 mL), dried (MgSO 4), filtered,
and concentrated in vacuo. The resulting residue was purified by flash chromatography
(hexanes:EtOAc 2:8) to afford 64 (345 mg, 1.40 mmol, 55%) as a pale yellow oil. 1H NMR
(600 MHz, chloroform-d) δ 7.43 (s, 1H), 6.51 (d, J = 16.2 Hz, 1H), 6.06 (dt, J = 16.2, 4.6 Hz,
1H), 4.30 (dd, J = 4.6, 1.9 Hz, 2H), 3.15-3.11 (m, 2H), 2.76-2.72 (m, 2H), 2.42 (s, 3H), 2.18 (s,
br, 1H); 13C NMR (151 MHz, chloroform-d) δ 201.2, 154.8, 146.4, 144.0, 137.3, 129.3, 128.1,
125.1, 120.5, 62.7, 36.5, 25.2, 21.3; IR (ATR) 3409, 2924, 1710, 1614, 1536, 1381, 1314, 1124,
1022 cm-1; HRMS (ESI) calculated for C13H14NO4 (M+H+) 248.09, found 248.0928.
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6-(3-methoxy-1-propenyl)-2,3-dihydro-5-methyl-7-nitroinden-1one (81). To an oven-dried flask equipped with a cold water condenser were added 79 (601
mg, 2.23 mmol), PdCl2(PPh3)2 (32 mg, 0.05 mmol), and PPh3 (24 mg, 0.09 mmol), and the
system was purged with N2. 1,4-dioxane (anhydrous, 15 mL) was added via syringe, and the
solution was stirred at ambient temperature. (E)-tributyl(3-methoxy-1-propenyl)stannane
(80, 1.05 g, 2.90 mmol) in 1,4-dioxane (anhydrous, 7 mL) was added via syringe and the
solution was heated to 110 °C for 120 h. The resulting reaction mixture was cooled to
ambient temperature and quenched with H2O (20 mL). Solution was extracted with EtOAc
(3 x 30 mL). The combined organics were washed with brine (3 x 30 mL), dried (MgSO 4),
filtered, and concentrated in vacuo. The resulting residue was purified by flash
chromatography (hexanes:EtOAc 1:1) to afford 81 (467 mg, 1.79 mmol, 80%) as an orange
solid. mp = 109-113 °C; 1H NMR (400 MHz, chloroform-d) δ 7.43 (s, 1H), 6.49 (d, J = 16.2 Hz,
1H), 5.99 (dt, J = 16.2, 5.0 Hz, 1H), 4.05 (dd, J = 5.0, 1.8 Hz, 2H), 3.39 (s, 3H), 3.16-3.10 (m,
2H), 2.78-2.73 (m, 2H), 2.43 (s, 3H); 13C NMR (151 MHz, chloroform-d) δ 200.9, 154.8, 146.2,
134.9, 131.9, 129.3, 128.2, 125.2, 122.0, 72.2, 58.3, 36.5, 25.2, 21.4; IR (ATR) 2929, 1716,
1615, 1539, 1441, 1382, 1315, 1186, 1120 cm-1; HRMS (ESI) calculated for C14H16NO4 (M+H+)
262.1074, found 262.1084.
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3-methoxy-5-(3-methoxy-1-propenyl)-6-methyl-4-nitroindene
(83). 81 (101 mg, 0.39 mmol) was dissolved in MeOH (3 mL), and p-toluenesulfonic acid (3
mg, 0.02 mmol) was added, followed by trimethyl orthoformate (84 μL, 0.77 mmol). The
resulting solution was stirred at ambient temperature for 16 h before being diluted with
EtOAc (5 mL) and quenched with a solution of NaOH (1M, 5 mL). This solution was extracted
with EtOAc (3 x 10 mL), and the combined organics were dried (MgSO4), filtered, and
concentrated in vacuo. The resulting residue was purified by flash chromatography
(hexanes:EtOAc 7:3 to 1:1 gradient) to afford 83 (13 mg, 0.05 mmol, 12%) as a viscous
yellow oil and unreacted 81 (11 mg, 0.04 mmol, 11%). Analytical data for 83: 1H NMR (600
MHz, chloroform-d) δ 7.30 (s, 1H), 6.53 (d, J = 16.3 Hz, 1H), 5.94 (dt, J = 16.2, 5.4 Hz, 1H), 5.35
(t, J = 2.4 Hz, 1H), 4.07-4.05 (m, 2H), 3.79 (s, 3H), 3.38 (s, 3H), 3.30 (d, J = 2.3 Hz, 2H), 2.36 (s,
3H);

13C

NMR (151 MHz, chloroform-d) δ 156.2, 143.8, 135.0, 133.3, 128.0, 126.9, 126.8,

126.5, 124.2, 100.0, 72.6, 58.0, 57.3, 33.6, 20.6; IR (ATR) 2927, 1712, 1613, 1533, 1379, 1116
cm-1; HRMS (ESI) calculated for C13H14NO4 (M+H+) 276.12, found 276.1232.

6-(1,2-epoxy-3-hydroxypropyl)-2,3-dihydro-5-methyl-7nitroinden-1-one (89). 64 (340 mg, 1.40 mmol) was dissolved in CH2Cl2 (10 mL), and
solution was cooled to 0 °C. 3-chloroperoxybenzoic acid (m-CPBA, 70-75%/wt, 1.38 g, 5.60
mmol) was added in portions. The resulting suspension was warmed to ambient
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temperature and stirred for 16 h. The reaction mixture was quenched by slow addition of
saturated Na2SO3 (aq, 10 mL) and diluted with CH2Cl2 (5 mL), then washed with saturated
NaHCO3 (aq, 10 mL) and brine (10 mL). The organics were dried (Na2SO4), filtered, and
concentrated in vacuo. The resulting residue was purified by flash chromatography (EtOAc)
to afford 89 (268 mg, 1.02 mmol, 74%) as a colorless oil. 1H NMR (600 MHz, chloroform-d)
δ 7.46 (s, 1H), 4.07 (d, J = 2.3 Hz, 1H), 3.99 (dd, J = 13.0, 2.6 Hz, 1H), 3.82 (dd, J = 13.0, 3.1 Hz,
1H), 3.15-3.12 (m, 3H), 2.75-2.72 (m, 2H), 2.55 (s, 3H), 2.36 (s, br, 1H); 13C NMR (151 MHz,
chloroform-d) δ; IR (ATR) 3419, 2927, 1713, 1618, 1541, 1372, 1309, 1121, 903 cm-1; HRMS
(ESI) calculated for C13H14NO5 (M+H+) 264.0866, found 264.0876.

6,7-dihydro-2-(hydroxymethyl)-4-methylcyclopent[g]-(Nhydroxy)indol-8(1H)-one (90). Method from Table 6, entry 2: To a thick-walled pressure
tube was added 89 (84 mg, 0.32 mmol) and Pd/C (10% Pd, 7 mg, 0.006 mmol). Absolute
EtOH (3 mL) was added, and the resulting suspension was charged with 40 psi H 2. The
reaction mixture was heated to 50 °C and stirred for 12 h. The solution was cooled to ambient
temperature and filtered over Celite, rinsing with hot EtOH, and the filtrate was concentrated
in vacuo. The resulting residue was purified by flash chromatography (hexanes:EtOAc 1:1)
to afford 90 (27 mg, 0.12 mmol, 37%) as a yellow solid. mp = 164-166 °C; 1H NMR (400 MHz,
DMSO-d6/chloroform-d) δ 11.69 (s, br, 1H), 6.87 (s, 1H), 6.39 (s, 1H), 4.98 (t, J = 5.8 Hz, 1H),
4.73 (d, J = 5.6 Hz, 2H), 3.26-3.22 (m, 2H), 2.77-2.73 (m, 2H), 2.55 (s, 3H); 1H NMR (400 MHz,
chloroform-d) δ 12.17 (s, 1H), 6.88 (s, 1H), 6.39 (s, 1H), 4.86 (d, J = 6.6 Hz, 2H), 3.31-3.27 (m,
2H), 2.84-2.79 (m, 2H), 2.57 (s, 3H), 2.23 (t, J = 6.6 Hz, 1H);

13C

NMR (101 MHz, DMSO78

d6/chloroform-d) δ 206.8, 153.0, 140.4, 135.3, 125.6, 121.1, 118.4, 116.6, 95.2, 54.3, 35.5,
26.9, 18.7; IR (ATR) 3350, 2925, 1614, 1367, 1299, 1158, 1076, 1006 cm-1; HRMS (ESI)
calculated for C13H14NO3 (M+H+) 232.0968, found 232.0978.

6,7-dihydro-2,4-dimethylcyclopent[g]indol-8(1H)-one

(91).

Method

from Table 6, entry 3: To a thick-walled pressure tube was added 89 (58 mg, 0.22 mmol) and
Pd/C (10% Pd, 12 mg, 0.011 mmol). Absolute EtOH (3 mL) was added, and the resulting
suspension was charged with 40 psi H2. The reaction mixture was heated to 50 °C and stirred
for 16 h. The solution was cooled to ambient temperature and filtered over Celite, rinsing
with hot EtOH, and the filtrate was concentrated in vacuo. The resulting residue was purified
by flash chromatography (hexanes:EtOAc 1:1) to afford 91 as a pale-orange viscous oil. 1H
NMR (400 MHz, chloroform-d) δ 9.19 (s, br, 1H), 6.93 (s, 1H), 6.27 (s, 1H), 3.23-3.16 (m, 2H),
2.74-2.68 (m, 2H), 2.58 (s, 3H), 2.48 (s, 3H); 13C NMR (101 MHz, DMSO-d6/chloroform-d) δ
206.7, 151.4, 138.7, 135.0, 130.3, 128.1, 119.2, 117.7, 99.0, 36.5, 26.6, 19.7, 13.6; IR (ATR)
3327, 2921, 1678, 1633, 1554, 1298 cm-1; HRMS (ESI) calculated for C13H14NO (M+H+)
200.1075, found 200.1070.
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Dilemmaone B (53).
Method A (Table 6, entry 4): 90 (17 mg, 0.074 mmol) was reacted with Pd/C (10% Pd, 4 mg,
0.004 mmol) and EtOH (3mL) under 40 psi H2 as described for 91 (50 °C, 2 h) to afford after
purification (hexanes:EtOAc 2:8) 53 (4 mg, 0.02 mmol, 27%) as an off-white solid.
Method B (Table 6, entry 5): To a thick-walled pressure tube was added 89 (126 mg, 0.48
mmol) and PtO2 (3 mg, 0.010 mmol). Absolute EtOH (3 mL) was added, and the resulting
suspension was charged with 40 psi H2. The reaction mixture was heated to 50 °C and stirred
for 3 h. The solution was cooled to ambient temperature and filtered over Celite, rinsing with
hot EtOH, and the filtrate was concentrated in vacuo. The resulting residue was purified by
flash chromatography (hexanes:EtOAc 2:8) to afford 53 (49 mg, 0.23 mmol, 48%) as an offwhite solid.
Analytical data for 53: mp = 188-190 °C; 1H NMR (400 MHz, chloroform-d) δ 9.70, 6.97, 6.49,
4.87, 3.21, 2.73, 2.60, 2.04 (multiplicity not reported as solubility in chloroform-d is poor—
full analysis was done in DMSO-d6); 1H NMR (600 MHz, DMSO-d6) δ 11.30 (s, br, 1H), 6.94 (s,
1H), 6.43 (s, 1H), 5.07 (t, J = 6.1 Hz, 1H), 4.61 (d, J = 6.1 Hz, 2H), 3.15-3.11 (m, 2H), 2.65-2.60
(m, 2H), 2.53 (s, 3H); 13C NMR (151 MHz, DMSO-d6) δ 204.7, 151.4, 140.7, 138.1, 129.4, 127.3,
119.3, 117.2, 98.1, 56.6, 35.9, 26.0, 19.2; IR (ATR) 3376, 2851, 1634., 1556, 1439, 1299, 1233,
1125, 1025 cm-1; HRMS (ESI) calculated for C13H14NO2 (M+H+) 216.1019, found 216.1028.
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6-(1,2-epoxy-3-methoxypropyl)-2,3-dihydro-5-methyl-7nitroinden-1-one (92). 81 (220 mg, 0.84 mmol) was reacted with m-CPBA (70-75%/wt,
830 mg, 3.36 mmol) in CH2Cl2 (5mL) as described for 89 to afford after purification
(hexanes:EtOAc 2:8) 92 (119 mg, 0.43 mmol, 51%) as a colorless oil. 1H NMR (400 MHz,
chloroform-d) δ 7.46 (s, 1H), 3.95 (d, J = 1.8 Hz, 1H), 3.77(dd, J = 11.7, 2.8 Hz, 1H), 3.54 (dd, J
= 11.7, 4.8 Hz, 1H), 3.42 (s, 3H), 3.18-3.10 (m, 3H), 2.77-2.70 (m, 2H), 2.56 (s, 3H); 13C NMR
(101 MHz, chloroform-d) δ 216.0, 200.5, 186.8, 155.9, 147.2, 130.0, 126.0, 125.2, 71.2, 59.4,
57.7, 51.4, 36.5, 25.2, 20.2; IR (ATR) 2929, 1714, 1618, 1541, 1449, 1371, 1309, 1110, 907
cm-1; HRMS (ESI) calculated for C14H16NO5 (M+H+) 278.1028, found 278.1025.

Dilemmaone A (52).
Method A (Scheme 19): 92 (88 mg, 0.32 mmol) was reacted with Pd/C (10% Pd, 7 mg, 0.006
mmol) and EtOH (3mL) under 40 psi H2 as described for 90 (50 °C, 16 h) to afford after
purification (hexanes:EtOAc 1:1) 52 (22 mg, 0.10 mmol, 30%) as an off-white solid.
Method B (Scheme 19): 92 (119 mg, 0.43 mmol) was reacted with PtO2 (2 mg, 0.009 mmol)
and EtOH (3mL) under 40 psi H2 as described for 53 (50 °C, 4 h) to afford after purification
(hexanes:EtOAc 1:1) 52 (25 mg, 0.11 mmol, 25%) as an off-white solid.
mp = 151-154 °C; 1H NMR (400 MHz, CDCl3) δ 9.52 (s, br, 1H), 6.95 (s, 1H), 6.49 (d, J = 2.2 Hz,
1H), 4.61 (s, 2H), 3.37 (s, 3H), 3.22-3.17 (m, 2H), 2.73-2.69 (m, 2H), 2.59 (s, 3H).; 1H NMR
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(600 MHz, DMSO-d6) δ 11.59 (s, br, 1H), 6.95 (s, 1H), 6.52 (d, J = 1.8 Hz, 1H), 4.54 (s, 2H), 3.28
(s, 3H), 3.14-3.11 (m, 2H), 2.64-2.61 (m, 2H), 2.54 (s, 3H); 13C NMR (151 MHz, DMSO-d6) δ
204.6, 152.0, 138.3, 136.2, 129.5, 127.3, 119.5, 117.3, 100.4, 66.4, 57.2, 35.9, 26.0, 19.2; IR
(ATR) 3339, 2920, 1657, 1560, 1294, 1128 cm-1; HRMS (ESI) calculated for C14H16NO2
(M+H+) 230.1181, found 230.1174.

4-Amino-6-bromo-2,3-dihydro-5-methylinden-1-one (95). 78 (440 mg,
1.63 mmol) was combined in a thick-walled glass pressure tube with Pd/C (10% Pd, 35 mg,
0.03 mmol) and absolute EtOH (6 mL). The resulting suspension was charged with 40 psi H2
and the system was heated to 50 °C and stirred for 21 h. The reaction mixture was cooled to
ambient temperature and filtered over Celite, rinsing with hot EtOH. The combined filtrates
were concentrated in vacuo, and without further purification 95 (391 mg, 1.29 mmol, 79%)
was obtained as a tan solid. mp = 183-192 °C; 1H NMR (400 MHz, DMSO-d6) δ 7.01 (s, 1H),
5.56 (br, s, 2H), 2.78 (m, 2H), 2.64-2.60 (m, 2H), 2.26 (s, 3H); 13C NMR (100 MHz, DMSO-d6)
δ 205.6, 145.4, 139.1, 136.1, 124.5, 123.6, 112.8, 35.9, 23.1, 17.6; IR (ATR) 3346, 2910, 1693,
1632, 1587, 1429, 1294, 1094 cm-1; HRMS (ESI, negative mode) calculated for C10H9BrNO
(M-H+) 239.9853, found 239.9847.

6-Bromo-2,3-dihydro-4-hydroxy-5-methylinden-1-one (96). 95 (481 mg,
2.01 mmol) was suspended in H2O (7 mL), and concentrated H2SO4 was added dropwise until
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dissolution of the solid (approx.. 8 mL). This solution was heated to 45 °C and stirred for 30
min. The solution was removed from heat and allowed to cool to ambient temperature before
being placed in an ice bath. A solution of NaNO2 (420 mg, 6.04 mmol) in H2O (3 mL) was
added dropwise, and the resulting solution stirred at 0 °C for 10 min before being heated to
reflux and stirred for 16 h. The resulting mixture was cooled to ambient temperature and
then added slowly in portions to a flask of ice water. Upon addition, a dark precipitate was
immediately formed. The suspension was filtered rinsing with cold H 2O, and the solid was
dried in vacuo to afford 96 (185 mg, 0.77 mmol, 38%) as a brown solid without further
purification. 1H NMR (400 MHz, DMSO-d6) δ 9.85 (s, 1H), 7.31 (s, 1H), 2.96-2.92 (m, 2H), 2.652.62 (m, 2H), 2.33 (s, 3H).

6-Bromo-2,3-dihydro-4-hydroxy-5-methyl-7-nitroinden-1-one (97). 96
(88 mg, 0.36 mmol) was reacted with fuming HNO3 (2 mL) and conc. H2SO4 (5 drops) as
described for 70 (-20 °C, 90 min). After chromatography (hexanes:EtOAc 1:1), 97 (33 mg,
0.12 mmol, 32%) was obtained as an orange solid. 1H NMR (400 MHz, chloroform-d) δ 2.922.87 (m, 2H), 2.84-2.79 (m, 2H), 1.68 (s, 3H).

3-(2-nitrophenyl)-3-buten-1-ol (106). To a round-bottomed flask
equipped with cold-water condenser was added Pd(dba)2 (11 mg, 0.02 mmol), dppf (21 mg,
0.04 mmol), and urotropine (104 mg, 0.74 mmol), and the system was purged with N2. DMA
(3 mL) was added via syringe, and the solution was heated to 105 °C. A mixture of 3-buten83

1-ol (63 μL, 0.74 mmol) and 105 (100 mg, 0.37 mmol) in DMA (2 mL) was added via syringe,
and the solution stirred at 105 °C for 72 h. The resulting mixture was cooled to ambient
temperature and quenched with H2O then extracted with EtOAc (3 x 10 mL). The combined
organics were washed with saturated NaHCO3 (aq., 10 mL) and brine (10 mL), dried (MgSO4),
and solvents were removed in vacuo. The resulting residue was purified by flash
chromatography (hexanes:EtOAc 7:3 to 2:8) to afford 106 (34 mg, 0.18 mmol, 47%) as an
orange oil as a mixture of stereoisomers (106/107 = 6.3:1 by 1H NMR), and 2-nitrophenol
(6 mg, 0.04 mmol, 11%). Analytical data for the 6.3:1 mixture (data provided for compound
106): 1H NMR (400 MHz, chloroform-d) δ 7.86 (d, J = 8.2 Hz, 1H), 7.57 (t, J = 7.6 Hz, 1H), 7.43
(t, J = 7.8 Hz, 1H), 7.35 (d, J = 7.6 Hz, 1H), 5.30 (s, 1H), 5.08 (s, 1H), 3.72 (t, J = 5.8 Hz, 2H),
2.70 (t, J = 6.0 Hz, 2H), 1.84 (br s, 1H).

4-(2-nitrophenyl)-3-buten-1-ol (107). Method used to obtain 107 as
the major isomer: To a round-bottomed flask equipped with cold-water condenser was
added 105 (500 mg, 1.85 mmol), Pd(OAc)2 (20 mg, 0.09 mmol) and PPh3 (50 mg, 0.19 mmol),
and the system was purged with N2. NEt3 (9.25 mL) was added via syringe, followed by 3buten-1-ol (320 μL, 3.7 mmol) via syringe. The solution was heated to 80 °C and stirred for
18 h. The resulting reaction mixture was cooled to ambient temperature and quenched with
H2O then extracted with EtOAc (3 x 10 mL). The combined organics were washed with
saturated NaHCO3 (aq., 10 mL) and brine (10 mL), dried (MgSO4), and solvents were
removed in vacuo. The resulting residue was purified by flash chromatography
(hexanes:EtOAc 7:3 to 1:1) to afford 107 (22 mg, 0.11 mmol, 6%) as an orange oil as a
mixture of stereoisomers (major/minor = 3.6:1 by 1H NMR). Analytical data for the 3.6:1
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mixture: 1H NMR (400 MHz, chloroform-d, major isomer) δ 7.90 (dd, J = 8.2, 1.2 Hz, 1H), 7.56
(dtd, J = 15.6, 8.1, 1.4 Hz, 2H), 7.41-7.33 (m, 2H), 6.95 (d, J = 15.7 Hz, 1H), 6.23 (dt, J = 15.7,
7.1 Hz, 1H), 3.81 (t, J = 6.2 Hz, 2H), 2.55 (qd, J = 6.3, 1.4 Hz, 2H); 1H NMR (400 MHz,
chloroform-d, minor isomer, partial data) δ 7.85 (dd, J = 8.1, 1.3 Hz, 1H), 7.43 (td, J = 7.8, 1.5
Hz, 2H), 6.86 (d, J = 11.5 Hz, 1H).

3-(2-bromo-6-nitrophenyl)-3-buten-1-ol (110). 108 (520 mg, 1.49
mmol) was reacted with 3-buten-1-ol (256 μL, 2.98 mmol), Pd(dba)2 (43 mg, 0.08 mmol),
dppf (83 mg, 0.15 mmol), and urotropine (417 mg, 2.98 mmol) in DMA (7 mL) as described
for 106 (105 °C, 72 h) to afford after purification by flash chromatography (hexanes:EtOAc
7:3) 110 (27 mg, 0.10 mmol, 7%) as an orange oil. 1H NMR (400 MHz, chloroform-d) δ 7.83
(d, J = 8.0 Hz, 1H), 7.75 (d, J = 8.1 Hz, 1H), 7.31 (t, J = 8.1 Hz, 1H), 5.41 (s, 1H), 5.07 (s, 1H),
3.89 (t, J = 6.2 Hz, 2H), 2.88-2.67 (m, 2H).

3-(3-bromo-2-nitrophenyl)-3-buten-1-ol (112). 109 (231 mg, 0.66
mmol) was reacted with 3-buten-1-ol (113 μL, 1.32 mmol), Pd(dba)2 (19 mg, 0.04 mmol),
dppf (37 mg, 0.07 mmol), and urotropine (185 mg, 1.32 mmol) in DMA (5 mL) as described
for 106 (105 °C, 72 h) to afford after purification by flash chromatography (hexanes:EtOAc
7:3) 112 (12 mg, 0.04 mmol, 7%) as an orange oil as a mixture of isomers (1:11 by 1H NMR)
and 3-bromo-2-nitrophenol (113, 75 mg, 0.34 mmol, 52%). Analytical data for the 1:11
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mixture (data provided for compound 112): 1H NMR (400 MHz, chloroform-d, partial data)
δ 5.33 (s, 1H), 5.19 (s, 1H), 3.69 (t, J = 6.0 Hz, 2H), 2.69-2.63 (m, 2H).

3-bromo-2-nitrophenol (113). 109 (231 mg, 0.66 mmol) was reacted with 3buten-1-ol (113 μL, 1.32 mmol), Pd(dba)2 (19 mg, 0.04 mmol), dppf (37 mg, 0.07 mmol), and
urotropine (185 mg, 1.32 mmol) in DMA (5 mL) as described for 106 (105 °C, 72 h) to afford
after purification by flash chromatography (hexanes:EtOAc 7:3) 112 (12 mg, 0.04 mmol, 7%)
as an orange oil as a mixture of isomers (1:11 by 1H NMR) and 113 (75 mg, 0.34 mmol, 52%).
Analytical data for 113: 1H NMR (400 MHz, chloroform-d) δ 9.38 (br, s, 1H), 7.33-7.28 (m,
2H), 7.15-7.08 (m, 1H).

(S)-methyl-2-(tert-butylcarbonylamino)-4-(2-nitrophenyl)pent-4enoate (122). 105 (100 mg, 0.37 mmol) was reacted with 121 (170 mg, 0.74 mmol),
Pd(dba)2 (21 mg, 0.04 mmol), dppf (25 mg, 0.04 mmol), and urotropine (104 mg, 0.74 mmol)
in DMA (5 mL) as described for 106 (105 °C, 72 h) to afford after purification by flash
chromatography (hexanes:EtOAc 7:3) an orange oil as a mixture of compounds (1.5:1 122
and 123 (32%) : 105 (19%) by 1H NMR). Analytical data for the mixture of stereoisomers
(data provided for compound 122): 1H NMR (400 MHz, chloroform-d) δ 8.18 (d, J = 8.5 Hz,
1H), 7.94 (d, J = 8.0 Hz, 1H), 7.50-7.44 (m, 1H), 7.35 (d, J = 7.7 Hz, 1H), 5.28 (s, 1H), 5.14 (s,
1H), 4.35 (d, J = 10.4 Hz, 1H), 3.58 (s, 3H), 3.01-2.90 (m, 1H), 2.77 (dd, J = 15.5, 7.9 Hz, 2H),
1.41 (s, 9H).
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(S)-methyl-2-(tert-butylcarbonylamino)-5-(2nitrophenyl)pent-4-enoate (123). 105 (100 mg, 0.37 mmol) was reacted with 121 (170
mg, 0.74 mmol), Pd(dba)2 (21 mg, 0.04 mmol), dppf (25 mg, 0.04 mmol), and urotropine (104
mg, 0.74 mmol) in DMA (5 mL) as described for 106 (105 °C, 72 h) to afford after purification
by flash chromatography (hexanes:EtOAc 7:3) an orange oil as a mixture of compounds
(1.5:1 122 and 123 (32%) : 105 (19%) by 1H NMR). Analytical data for the mixture of
stereoisomers (data provided for compound 123): 1H NMR (400 MHz, chloroform-d, partial
data) δ 6.96-6.77 (m, 1H), 6.14-6.01 (m, 1H), 4.58-4.44 (m, 1H), 3.78 (s, 3H), 2.71-2.58 (m,
1H), 1.43 (s, 9H).

3-ethanol-1H-indole (124). To a thick-walled pressure tube equipped with
stir bar was added 106 (50 mg, 0.26 mmol), Pd(OAc)2 (5 mg, 0.02 mmol), and PPh3 (20 mg,
0.06 mmol). A 2:1 mixture of MeOH:DMF (2 mL) was added, and the system was charged
with 90 psi CO. The solution was heated to 60 °C and stirred vigorously for 24 h. The resulting
solution was cooled to ambient temperature and extracted with EtOAc (3 x 5 mL). The
combined organics were washed with H2O (2 x 5 mL), dried (MgSO4), and solvents were
removed in vacuo. The resultant residue was purified via flash chromatography
(hexanes:EtOAc 1:1) to afford 124 (31 mg, 0.19 mmol, 74%) as an off-white solid. 1H NMR
(400 MHz, chloroform-d) δ 8.11 (br s, 1H), 7.63-7.58 (m, 1H), 7.33 (d, J = 8.1 Hz, 1H), 7.227.17 (m, 1H), 7.12 (ddd, J = 7.9, 7.1, 0.9 Hz, 1H), 7.01 (d, J = 2.3 Hz, 1H), 3.88 (t, J = 6.4 Hz, 2H),
3.05-2.97 (m, 2H), 1.71 (br s, 1H).
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3-hexyl-1H-indole (126). 120 (49 mg, 0.21 mmol) was reacted with
Pd(OAc)2 (5 mg, 0.02 mmol), and PPh3 (22 mg, 0.08 mmol) in CH3CN (3 mL) under 90 psi CO
as described for 124 (100 °C, 24 h) to afford after purification by flash chromatography
(hexanes:EtOAc 9:1) 126 (16 mg, 0.08 mmol, 37%) and unreacted starting material (120, 6
mg, 0.03 mmol, 13%). Analytical data for 126: 1H NMR (400 MHz, chloroform-d) δ 7.87 (s,
1H), 7.61 (d, J = 7.6 Hz, 1H), 7.34 (d, J = 8.1 Hz, 1H), 7.18 (t, J = 7.5 Hz, 1H), 7.10 (t, J = 7.4 Hz,
1H), 6.96 (s, 1H), 2.75 (t, J = 7.6 Hz, 2H), 1.71 (m, J = 7.6 Hz, 2H), 1.45-1.28 (m, 6H), 0.90 (m,
3H);

13C

NMR (101 MHz, chloroform-d) δ 136.3, 131.6, 127.6, 121.8, 120.9, 119.0, 117.2,

111.0, 31.8, 30.1, 29.3, 25.1, 22.7, 14.1.

N-tert-butoxycarbonyl-tryptophan methyl ester (127). The mixture
of 122 with 123, with 105 (80 mg, ~0.23 mmol) was reacted with Pd(dba)2 (8 mg, 0.013
mmol), dppp (5 mg, 0.013 mmol), 1,10-phenanthroline (5 mg, 0.03 mmol) in DMF (3 mL)
under 90 psi CO as described for 124 (120 °C, 48 h) to afford after purification by flash
chromatography (hexanes:EtOAc 7:3) two isolated compounds: 127 (16 mg, 0.05 mmol,
22%) and 128 (7 mg, 0.02 mmol, 10%). Analytical data for 127: 1H NMR (400 MHz,
chloroform-d) δ 8.16 (s, 1H), 7.55 (d, J = 7.4 Hz, 1H), 7.35 (d, J = 8.1 Hz, 1H), 7.19 (t, J = 7.3
Hz, 1H), 7.12 (t, J = 7.4 Hz, 1H), 7.02-6.98 (m, 1H), 5.09 (d, J = 7.8 Hz, 1H), 4.65 (d, J = 7.8 Hz,
1H), 3.68 (s, 3H), 3.29 (s, 2H), 1.43 (s, 9H); 13C NMR (101 MHz, chloroform-d) δ 172.8, 155.2,
136.0, 129.6, 122.7, 122.2, 119.6, 118.7, 111.1, 110.2, 79.8, 54.1, 52.2, 28.3, 27.9.
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α-[[1,1-dimethylethoxy)carbonyl]amino]-1H-indole-2propanoic acid methyl ester (128). The mixture of 122 with 123, with 105 (80 mg, ~0.23
mmol) was reacted with Pd(dba)2 (8 mg, 0.013 mmol), dppp (5 mg, 0.013 mmol), 1,10phenanthroline (5 mg, 0.03 mmol) in DMF (3 mL) under 90 psi CO as described for 124 (120
°C, 48 h) to afford after purification by flash chromatography (hexanes:EtOAc 7:3) two
isolated compounds: 127 (16 mg, 0.05 mmol, 22%) and 128 (7 mg, 0.02 mmol, 10%).
Analytical data for 128: 1H NMR (400 MHz, chloroform-d) δ 8.31 (s, 1H), 7.53 (d, J = 8.8 Hz,
1H), 7.32 (d, J = 7.8 Hz, 1H), 7.21 (d, J = 7.1 Hz, 2H), 6.28 (s, 1H), 5.13 (d, J = 8.5 Hz, 1H), 4.66
(s, 1H), 3.76 (s, 3H), 3.29 (d, J = 4.1 Hz, 2H), 1.43 (s, 9H).

1-oxide-4-quinolinecarbonitrile (141).
Method A: A round-bottomed flask was charged with 140 (111 mg, 0.62 mmol) and 18crown-6 (49 mg, 0.19 mmol), and the system was purged with N2. THF (5 mL) was added via
syringe, and the solution was cooled to -78 °C. A suspension of KOtBu (179 mg, 1.60 mmol)
in THF (1 mL) was added slowly via syringe, followed by dropwise addition of acetaldehyde
(346 μL, 6.17 mmol) via syringe. The resulting solution was stirred at -78 °C for 2 h. The
reaction mixture was allowed to warm to ambient temperature and was quenched by slow
addition of a saturated solution of NH4Cl (aq) and extracted with CH2Cl2 (3 x 10 mL). The
combined organics were washed with brine (10 mL), dried (MgSO4), and solvents were
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removed in vacuo. The resulting residue was purified by flash chromatography (EtOAc) to
afford 141 (55 mg, 0.32 mmol, 47%) as a brown solid.
Method B: A round-bottomed flask was charged with 140 (1.01 g, 6.17 mmol) and the system
was purged with N2. THF (43 mL) was added via syringe, and the solution was cooled to -78
°C. A suspension of KOtBu (2.07 g, 18.5 mmol) in THF (8.6 mL) was added slowly via syringe,
followed by dropwise addition of acetaldehyde (3.46 mL, 61.7 mmol) via syringe. The
resulting solution was stirred at -78 °C for 2 h. The reaction mixture was allowed to warm to
ambient temperature and was quenched by slow addition of a saturated solution of NH4Cl
(aq) and extracted with CH2Cl2 (3 x 20 mL). The combined organics were washed with brine
(30 mL), dried (MgSO4), and solvents were removed in vacuo. The resulting residue was
purified by flash chromatography (EtOAc) to afford 141 (698 mg, 4.10 mmol, 66%) as a
brown solid.
Analytical data for 141: 1H NMR (400 MHz, chloroform-d) δ 8.74 (dd, J = 8.6, 1.8 Hz, 1H), 8.50
(d, J = 6.4 Hz, 1H), 8.23 (dd, J = 7.0, 2.6 Hz, 1H), 7.92-7.82 (m, 2H), 7.67 (d, J = 6.4 Hz, 1H).

2-methyl-4-quinolinecarbonitrile (145). A round-bottomed flask was
charged with 141 (36 mg, 0.21 mmol) and the system was purged with N2. THF (2 mL) was
added via syringe, and the resulting solution was cooled to -30 °C. Methylmagnesium
bromide (3.0M solution in THF, 71 μL, 0.21 mmol) was added via syringe, and the reaction
mixture was stirred at -30 °C for 1 h. The solution was allowed to warm to ambient
temperature and stirred for an additional 1 h, during which time the reaction mixture
darkened in color. Upon completion, the reaction was quenched with H2O and extracted with
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EtOAc (3 x 10 mL). The combined organics were dried (MgSO4) and solvents were removed
in vacuo. The resulting residue was purified by flash chromatography (hexanes:EtOAc 1:1 to
EtOAc) to afford 145 (24 mg, 0.14 mmol, 68%). 1H NMR (400 MHz, chloroform-d) δ 8.75 (d,
J = 8.7 Hz,1H), 8.18 (d, J = 8.3 Hz, 1H), 7.86 (t, J = 7.9 Hz, 1H), 7.83-7.75 (m, 1H), 7.72 (s, 1H),
2.70 (s, 3H).

2-(2-methylpropyl)-4-quinolinecarbonitrile (146). A 2-necked roundbottomed flask equipped with a cold-water condenser and addition funnel was charged with
Mg (243 mg, 10.13 mmol) and I2 (crystals) and the system was purged with N2. The flask was
heated until a purple vapor was visible. A solution of 1-bromo-2-methylpropane (1.0 mL,
9.21 mmol) in THF (14 mL) was added via the addition funnel and the resulting solution was
stirred at ambient temperature for 2 h to afford a solution of the desired Grignard reagent.
A round-bottomed flask was charged with 141 (86 mg, 0.59 mmol) and the system was
purged with N2. THF (4 mL) was added via syringe, and the solution was cooled to -30 °C. An
aliquot of the Grignard solution (820 L, 9.0 mmol) was added via syringe, and the resulting
solution was stirred at -30 °C for 1 h. The solution was allowed to warm to ambient
temperature and stirred for an additional 1 h, during which time the reaction mixture
darkened in color. Upon completion, the reaction was quenched with H2O and extracted with
EtOAc (3 x 10 mL). The combined organics were dried (MgSO4) and solvents were removed
in vacuo. The resulting residue was purified by flash chromatography (hexanes:EtOAc 7:3
then EtOAc) to afford 146 (21 mg, 0.10 mmol, 17%) and recovered 141 (21 mg, 0.12 mmol,
20%).
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2-benzyl-4-quinolinecarbonitrile (147). 141 (200 mg, 1.18 mmol) was
reacted with benzylmagnesium bromide (288 μL, 1.18 mmol) in THF (8 mL) as described for
145 (-30 °C, 1 h, then ambient temperature, 1 h) to afford after purification by flash
chromatography (hexanes:EtOAc 7:3 then EtOAc) 147 (6 mg, 0.02 mmol, 2%) and recovered
141 (87 mg, 0.45 mmol, 44%). 1H NMR (400 MHz, chloroform-d) δ 8.78 (d, J = 8.7 Hz, 1H),
8.22 (dd, J = 8.2, 4.1 Hz, 1H), 8.16 (d, J = 8.3 Hz, 1H), 7.90-7.83 (m, 1H), 7.83-7.76 (m, 1H),
7.39 (d, J = 5.7 Hz, 3H), 7.31 (d, J = 6.9 Hz, 2H), 4.41 (s, 2H).
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Appendix
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Figure 9: Ethyl 2-(2-nitrophenyl)-2-butenoate (10)—1H NMR
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Figure 10: Ethyl 2-(2-nitrophenyl)-2-butenoate (10)—13C NMR
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Figure 11: Ethyl 1-methoxyindole-3-carboxylate (12)—1H NMR
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Figure 12: Ethyl 1-methoxyindole-3-carboxylate (12)—13C NMR
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Figure 13: Ethyl 1-benzyloxyindole-3-carboxylate (13)—1H NMR

105

Figure 14: Ethyl 1-benzyloxyindole-3-carboxylate (13)—13C NMR
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Figure 15: Methyl 1-(2-propen-1-yloxy)indole-3-carboxylate (14)—1H NMR
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Figure 16: Methyl 1-(2-propen-1-yloxy)indole-3-carboxylate (14)—13C NMR
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Figure 17: Methyl 1-methoxyindole-3-carboxylate (15)—1H NMR
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Figure 18: Methyl 1-methoxyindole-3-carboxylate (15)—13C NMR
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Figure 19: Ethyl 1-acetoxyindole-3-carboxylate (17)—1H NMR
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Figure 20: Ethyl 1-acetoxyindole-3-carboxylate (17)—13C NMR
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Figure 21: Ethyl 1-tosyloxyindole-3-carboxylate (18)—1H NMR
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Figure 22: Ethyl 1-tosyloxyindole-3-carboxylate (18)—13C NMR
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Figure 23: Ethyl 1-hydroxyindole-3-carboxylate (19)—1H NMR
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Figure 24: Ethyl 1-hydroxyindole-3-carboxylate (19)—13C NMR
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Figure 25: Ethyl 2-iodo-2-pentenoate (20)—1H NMR
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Figure 26: Ethyl 2-iodo-2-pentenoate (20)—13C NMR
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Figure 27: Ethyl 2-iodo-2-hexenoate (21)—1H NMR
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Figure 28: Ethyl 2-iodo-2-hexenoate (21)—13C NMR

120

Figure 29: Ethyl 2-iodo-2-octenoate (22)—1H NMR

121

Figure 30: Ethyl 2-iodo-2-octenoate (22)—13C NMR
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Figure 31: Ethyl 2-iodo-2-nonenoate (23)—1H NMR
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Figure 32: Ethyl 2-iodo-2-nonenoate (23)—13C NMR
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Figure 33: Ethyl 3-cyclohexyl-2-iodopropenoate (24)—1H NMR
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Figure 34: Ethyl 3-cyclohexyl-2-iodopropenoate (24)—13C NMR
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Figure 35: Ethyl 2-iodo-4-phenylpentenoate (25)—1H NMR
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Figure 36: Ethyl 2-iodo-4-phenylpentenoate (25)—13C NMR
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Figure 37: Methyl 2-(2-nitrophenyl)-2-hexenoate (27)—1H NMR
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Figure 38: Methyl 2-(2-nitrophenyl)-2-hexenoate (27)—13C NMR
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Figure 39: Methyl 2-(6-methoxy-2-nitrophenyl)-2-butenoate (29)—1H NMR
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Figure 40: Methyl 2-(6-methoxy-2-nitrophenyl)-2-butenoate (29)—13C NMR
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Figure 41: Methyl 2-(5-methoxy-2-nitrophenyl)-2-butenoate (30)—1H NMR
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Figure 42: Methyl 2-(5-methoxy-2-nitrophenyl)-2-butenoate (30)—13C NMR
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Figure 43: Methyl 2-(4-methoxy-2-nitrophenyl)-2-butenoate (31)—1H NMR

135

Figure 44: Methyl 2-(4-methoxy-2-nitrophenyl)-2-butenoate (31)—13C NMR
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Figure 45: Methyl 2-(3-methoxy-2-nitrophenyl)-2-butenoate (32)—1H NMR
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Figure 46: Methyl 2-(3-methoxy-2-nitrophenyl)-2-butenoate (32)—13C NMR
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Figure 47: Methyl 2-(5-carbomethoxy-2-nitrophenyl)-2-butenoate (33)—1H NMR
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Figure 48: Methyl 2-(5-carbomethoxy-2-nitrophenyl)-2-butenoate (33)—13C NMR
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Figure 49: Methyl 2-(4-carbomethoxy-2-nitrophenyl)-2-butenoate (34)—1H NMR
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Figure 50: Methyl 2-(4-carbomethoxy-2-nitrophenyl)-2-butenoate (34)—13C NMR
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Figure 51: Methyl 1-hydroxy-5-methoxyindole-3-carboxylate (35)—1H NMR
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Figure 52: Methyl 1-hydroxy-5-methoxyindole-3-carboxylate (35)—13C NMR
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Figure 53: Methyl 1,5-dimethoxyindole-3-carboxylate (36)—1H NMR
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Figure 54: Methyl 1,5-dimethoxyindole-3-carboxylate (36)—13C NMR
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Figure 55: Methyl 1-hydroxy-6-methoxyindole-3-carboxylate (37)—1H NMR
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Figure 56: Methyl 1-hydroxy-6-methoxyindole-3-carboxylate (37)—13C NMR
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Figure 57: Methyl 1,6-dimethoxyindole-3-carboxylate (38)—1H NMR
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Figure 58: Methyl 1,6-dimethoxyindole-3-carboxylate (38)—13C NMR
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Figure 59: Methyl 5-carbomethoxy-1-hydroxyindole-3-carboxylate (39)—1H NMR
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Figure 60: Methyl 5-carbomethoxy-1-hydroxyindole-3-carboxylate (39)—13C NMR
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Figure 61: Methyl 5-carbomethoxy-1-methoxyindole-3-carboxylate (40)—1H NMR
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Figure 62: Methyl 5-carbomethoxy-1-methoxyindole-3-carboxylate (40)—13C NMR
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Figure 63: Methyl 6-carbomethoxy-1-hydroxyindole-3-carboxylate (41)—1H NMR
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Figure 64: Methyl 6-carbomethoxy-1-hydroxyindole-3-carboxylate (41)—13C NMR
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Figure 65: Methyl 6-carbomethoxy-1-methoxyindole-3-carboxylate (42)—1H NMR
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Figure 66: Methyl 6-carbomethoxy-1-methoxyindole-3-carboxylate (42)—13C NMR
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Figure 67: 6-Amino-7-bromo-2,3-dihydro-5-methylinden-1-one (75)—1H NMR
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Figure 68: 6-Amino-7-bromo-2,3-dihydro-5-methylinden-1-one (75)—13C NMR
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Figure 69: N-(2,3-Dihydro-5-methyl-1-oxo-1H-inden-6-yl)acetamide (69)—1H NMR
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Figure 70: N-(2,3-Dihydro-5-methyl-1-oxo-1H-inden-6-yl)acetamide (69)—13C NMR
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Figure 71: N-(2,3-Dihydro-5-methyl-7-nitro-1-oxo-1H-inden-6-yl)acetamide (70)—1H
NMR
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Figure 72: N-(2,3-Dihydro-5-methyl-7-nitro-1-oxo-1H-inden-6-yl)acetamide (70)—13C
NMR
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Figure 73: 6-Amino-2,3-dihydro-5-methyl-7-nitroinden-1-one (71)—1H NMR
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Figure 74: 6-Amino-2,3-dihydro-5-methyl-7-nitroinden-1-one (71)—13C NMR
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Figure 75: 2,3-Dihydro-6-iodo-5-methyl-7-nitroinden-1-one (72)—1H NMR
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Figure 76: 2,3-Dihydro-6-iodo-5-methyl-7-nitroinden-1-one (72)—13C NMR
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Figure 77: 6-Bromo-2,3-dihydro-5-methylinden-1-one (76)—1H NMR
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Figure 78: 6-Bromo-2,3-dihydro-5-methylinden-1-one (76)—13C NMR
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Figure 79: 4-Bromo-2,3-dihydro-5-methylinden-1-one (77)—1H NMR
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Figure 80: 4-Bromo-2,3-dihydro-5-methylinden-1-one (77)—13C NMR
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Figure 81: 6-Bromo-2,3-dihydro-5-methyl-4-nitroinden-1-one (78)—1H NMR

173

Figure 82: 6-Bromo-2,3-dihydro-5-methyl-4-nitroinden-1-one (78)—13C NMR
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Figure 83: 6-Bromo-2,3-dihydro-5-methyl-7-nitroinden-1-one (79)—1H NMR
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Figure 84: 6-Bromo-2,3-dihydro-5-methyl-7-nitroinden-1-one (79)—13C NMR
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Figure 85: 6-(3-hydroxy-1-propenyl)-2,3-dihydro-5-methyl-7-nitroinden-1-one (64)—1H
NMR

177

Figure 86: 6-(3-hydroxy-1-propenyl)-2,3-dihydro-5-methyl-7-nitroinden-1-one (64)—13C
NMR
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Figure 87: 6-(3-methoxy-1-propenyl)-2,3-dihydro-5-methyl-7-nitroinden-1-one (81)—1H
NMR
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Figure 88: 6-(3-methoxy-1-propenyl)-2,3-dihydro-5-methyl-7-nitroinden-1-one (81)—13C
NMR
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Figure 89: 3-methoxy-5-(3-methoxy-1-propenyl)-6-methyl-4-nitroindene (83)—1H NMR
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Figure 90: 3-methoxy-5-(3-methoxy-1-propenyl)-6-methyl-4-nitroindene (83)—13C NMR
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Figure 91: 6-(1,2-epoxy-3-hydroxypropyl)-2,3-dihydro-5-methyl-7-nitroinden-1-one
(89)—1H NMR

183

Figure 92: 6-(1,2-epoxy-3-hydroxypropyl)-2,3-dihydro-5-methyl-7-nitroinden-1-one
(89)—13C NMR
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Figure 93: 6,7-dihydro-2-(hydroxymethyl)-4-methylcyclopent[g]-(N-hydroxy)indol8(1H)-one (90)—1H NMR (DMSO-d6/CDCl3)
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Figure 94: 6,7-dihydro-2-(hydroxymethyl)-4-methylcyclopent[g]-(N-hydroxy)indol8(1H)-one (90)—1H NMR (CDCl3)
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Figure 95: 6,7-dihydro-2-(hydroxymethyl)-4-methylcyclopent[g]-(N-hydroxy)indol8(1H)-one (90)—13C NMR
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Figure 96: 6,7-dihydro-2,4-dimethylcyclopent[g]indol-8(1H)-one (91)—1H NMR
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Figure 97: 6,7-dihydro-2,4-dimethylcyclopent[g]indol-8(1H)-one (91)—13C NMR
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Figure 98: Dilemmaone B (53)—1H NMR (CDCl3)
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Figure 99: Dilemmaone B (53)—1H NMR (DMSO-d6)

191

Figure 100: Dilemmaone B (53)—13C NMR (DMSO-d6)
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Figure 101: Dilemmaone B (53)—1H-15N gHSQCAD

aFull

1H-15N gHSQCAD for 53.

bExpansion

of spectrum a.
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Figure 102: Dilemmaone B (53)—gCOSY

aFull

gCOSY spectrum for 53.

bExpansion

of spectrum (a).
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Figure 103: Dilemmaone B (53)—gHSQCAD (1JHC)
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Figure 104: Dilemmaone B (53)—gHMBCAD Spectrum A
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Figure 105: Dilemmaone B (53)—gHMBCAD Spectrum B
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Figure 106: Dilemmaone B (53)—gHMBCAD Spectrum C
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Figure 107: 6-(1,2-epoxy-3-methoxypropyl)-2,3-dihydro-5-methyl-7-nitroinden-1-one
(92)—1H NMR
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Figure 108: 6-(1,2-epoxy-3-methoxypropyl)-2,3-dihydro-5-methyl-7-nitroinden-1-one
(92)—13C NMR
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Figure 109: Dilemmaone A (52)—1H NMR (CDCl3)
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Figure 110: Dilemmaone A (52)—1H NMR (DMSO-d6)
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Figure 111: Dilemmaone A (52)—13C NMR (DMSO-d6)
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Figure 112: Dilemmaone A (52)—1H-15N gHSQCAD
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Figure 113: Dilemmaone A (52)—gCOSY

aFull

gCOSY spectrum for 52.

bExpansion

of spectrum (a).
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Figure 114: 4-Amino-6-bromo-2,3-dihydro-5-methylinden-1-one (95)—1H NMR
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Figure 115: 4-Amino-6-bromo-2,3-dihydro-5-methylinden-1-one (95)—13C NMR
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Figure 116: 6-Bromo-2,3-dihydro-4-hydroxy-5-methylinden-1-one (96)—1H NMR
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Figure 117: 6-Bromo-2,3-dihydro-4-hydroxy-5-methyl-7-nitroinden-1-one (97)—1H NMR
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Figure 118: 3-(2-nitrophenyl)-3-buten-1-ol (106)—1H NMR

210

Figure 119: 4-(2-nitrophenyl)-3-buten-1-ol (107)—1H NMR
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Figure 120: 3-(2-bromo-6-nitrophenyl)-3-buten-1-ol (110)—1H NMR
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Figure 121: 3-(3-bromo-2-nitrophenyl)-3-buten-1-ol (112)—1H NMR

213

Figure 122: 3-bromo-2-nitrophenol (113)—1H NMR
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Figure 123: (S)-methyl-2-(tert-butylcarbonylamino)-4-(2-nitrophenyl)pent-4-enoate
(122)—1H NMR

215

Figure 124: (S)-methyl-2-(tert-butylcarbonylamino)-5-(2-nitrophenyl)pent-4-enoate
(123)—1H NMR
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Figure 125: 3-ethanol-1H-indole (124)—1H NMR

217

Figure 126: 3-hexyl-1H-indole (126)—1H NMR

218

Figure 127: 3-hexyl-1H-indole (126)—13C NMR

219

Figure 128: N-tert-butoxycarbonyl-tryptophan methyl ester (127)—1H NMR

220

Figure 129: N-tert-butoxycarbonyl-tryptophan methyl ester (127)—13C NMR

221

Figure 130: α-[[1,1-dimethylethoxy)carbonyl]amino]-1H-indole-2-propanoic acid methyl
ester (128)—1H NMR

222

Figure 131: 1-oxide-4-quinolinecarbonitrile (141)—1H NMR
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Figure 132: 2-methyl-4-quinolinecarbonitrile (145)—1H NMR
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Figure 133: 2-benzyl-4-quinolinecarbonitrile (147)—1H NMR
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